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Abstract 
Most human solid tumors present signs of genomic instability. Activated oncogenes 
have been proposed to induce genomic instability through the generation of 
replicative stress. In this thesis, we have sown that the expression of a constitutively 
active form of RAS oncogene promotes accelerated G1/S transition which leads to 
replicative stress and genomic instability. The resulting DNA damage present in these 
cells should activate the DDR response, however, RasV12 cells impair DNA damage 
signaling. Furthermore, RasV12 expression inhibits apoptosis through ERK. 
RAS is one of the most commonly mutated oncogenes, yet efficient therapies to treat 
RAS dependent tumors are still lacking. With this in mind, and based on our previous 
results, we decided to try to exploit the DNA damage present in these cells to 
selectively target them. In order to do so, we induced extra DNA damage with 
ionizing radiation and depleted ERK to promote the death of the cells. We used this 
strategy on RAS dependent tumors both benign and malignant tumors, and 
successfully targeted and killed tumor cells.  We propose that MEK inhibitors, that are 
being used in the treatment of metastatic melanomas, could be combined with 
radiation to improve the therapeutic outcomes.  
Aside from the previously described autonomous effects, we have also observed that 
RasV12 expression in the wing imaginal discs induces a non-autonomous phenotype. 
Wild type cells adjacent to RAS cells display signs of DNA damage, apoptosis and 
autophagy. The role of these non-autonomous effects is not clear; however, we 
hypothesize that they may play a role in metabolically supporting tumor growth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
19 
1. Cancer 
According to the National Cancer Institute and the World Health Organization, 
cancer is the name given to a series of related diseases where cells start to 
continuously proliferate and expand into surrounding tissues. Cancer is a disease of 
genetic origin as it arises as a consequence of mutations in oncogenes and tumor 
suppressor genes. This process can originate practically in any part of the body and 
in many cases metastasize to distant organs. One of the most common classifications 
is the one that subdivides tumors according to the tissue of origin: carcinomas being 
of epithelial origin, sarcomas of bone and soft tissues, leukemias of blood cells, etc.  
GLOBOCAN 2018, a yearly global cancer study, stated that cancer is the first or 
second cause of death in 91 of the 172 countries analyzed worldwide. In 2018 there 
will have been an estimated of 18,1 million new cases and 9,6 million cancer-related 
deaths. In both sexes, lung cancer is the most diagnosed and the leading cause of 
cancer-related death followed by breast, prostate and colorectal cancer. Cancer 
incidence and mortality are increasing worldwide due to different reasons like the 
aging of the population or the increased prevalence of risk factors (smoking, alcohol 
intake, obesity, physical inactivity…) associated with socioeconomic development.  
 
 
Figure 1. Cancer research in numbers. Number of entries in PubMed containing the 
word “cancer” every year since 1950 and the percentage they represent with respect to 
the total number of entries each year. Representation of data obtained from (Medline 
trends A. D. Corlan, 2004).  
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With its increasing incidence, also interest in cancer research has peaked. The 
amount of papers containing the word cancer indexed in PubMed has exponentially 
increased in the past ten years, accompanied by an increase in the percentage that 
these papers represent over the total publications (Fig 1).  
1.1. The hallmarks of cancer 
In the years of modern cancer research, knowledge of how tumor cells behave at a 
cellular and organismal level has been piling up. In the year 2000, Hanahan and 
Weinberg used all this information to propose that, although cancers are very 
heterogeneous and can arise from different types of cells and carry different 
oncogenic mutations, most of them are characterized by a series of traits that are 
shared and that direct malignant growth which they termed the hallmarks of cancer 
(Hanahan & Weinberg, 2000). 
- Self-sufficiency in growth signals. Normal cells depend on the presence of growth 
signals in order to proliferate. However, cancer cells become independent of these 
signals and continuously proliferate. This independence can be achieved by different 
mechanisms such as the tumor-induced production of mitogenic molecules, the 
deregulation of cell surface receptors or the constitutive activation of the signal 
transducers.  
- Insensitivity to growth-inhibitory signals. Normal cells need to respond to signaling 
cues that tell them to differentiate or become quiescent when proliferation is no 
longer necessary. However, cancer cells can evade or ignore those signals in order 
to continue to divide. 
- Evasion of programmed cell death. Apoptosis is induced in response to external 
signals as well as internal signals that monitor the wellbeing of the cell. Once it is 
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activated, a signaling cascade will lead to the activation of effector caspases 
(proteases that will carry out the death program). Apoptosis is generally seen as an 
anticancer barrier that needs to be circumvented in order to give rise to full-blown 
tumors. In fact, mutations in the master apoptosis regulator p53 are very commonly 
found in cancer.  
- Limitless replicative potential. This hallmark refers to the intrinsic capacity of cells to 
proliferate. Cellular senescence is a mechanism by which cells quit dividing. 
Senescence can be triggered as a consequence of the DNA damage response that 
is caused by the shortening of the telomeres with each cell cycle but can also arise 
as a consequence of reactive oxygen species (ROS) or other sources of damage. 
Furthermore, activated oncogenes can also lead to senescence (oncogene-induced 
senescence) that is why, like apoptosis, it can be seen as a cancer barrier that needs 
to be overridden in order for cancer to progress.  
- Sustained angiogenesis. Oxygen and nutrients are crucial for normal cell function. 
Both are provided through the bloodstream forcing cells to stay close enough to a 
blood vessel. In cancer, there is a very rapid proliferation of tumor cells which in turn 
induce angiogenesis, the proliferation of vascular cells in order to provide the tumor 
with the necessary nutrients.  
- Tissue invasion and metastasis. Many tumors invade neighboring tissues and 
eventually move out and metastasize into distant sites. In order to do so, tumor cells 
have to undergo an epithelial to mesenchymal transition, intravasate into the 
bloodstream and extravasate in the target site where it has to go back to an 
epithelial phenotype in order to survive and form a new tumor. Metastasis is the main 
cause of cancer deaths.  
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At the time, all of these general hallmarks seemed to describe the behavior of most 
human cancers. However, how these features were acquired was not clear yet.  A 
few years later Hanahan and Weinberg expanded on their original review and 
added two new hallmarks, the reprogramming of energy metabolism and the 
evasion of the immune system. But more importantly, they also included the fields 
proposal that genomic instability and inflammation are the ones behind the 
acquisition of all the hallmarks (Hanahan & Weinberg, 2011). In normal cells, DNA 
surveillance mechanisms keep mutation rates at minimum levels ensuring the correct 
transmission of the genetic information. However, in cancer cells, the mutation rates 
are much higher giving rise to the accumulation of mutations in oncogenes and 
tumors suppressors that drive the different hallmarks of cancer.  
1.2. Oncogene-induced DNA damage model for cancer 
development. 
Genomic instability, defined as the high rate of mutations within the genome, is 
considered as one of the enabling characteristics of cancer due to its capacity to 
promote the acquisition of the rest of characteristics that compose the so-called 
hallmarks of cancer.  
Genomic instability is present from early stages of tumorigenesis (Bartkova et al., 
2005; Gorgoulis et al., 2005) in both hereditary and sporadic tumors, however, the 
way by which genomic instability arises in these two cases seems to be different. 
Many hereditary tumors are associated with mutations in caretaker genes, that is 
genes involved in the repair of DNA damage. This is the case for Lynch syndrome, 
Bloom syndrome or Fanconi anemia (Kaseb & Hozayen, 2019). Germline mutations 
in caretaker genes predispose to cancer given that a single mutational event is 
needed to deplete the gene function. Once this happens, it can directly lead to 
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genomic instability as a consequence of the lack of repair of naturally occurring 
damage events. However, in sporadic tumors, mutations in caretaker genes are not 
that common, and if present they tend to appear at late stages. After genome-wide 
analysis of the mutational signature of different tumor stages, it was found that the 
most common mutations in cancer are in growth-regulating genes in the form of 
oncogenic gains such as EGFR or RAS and loss of tumor suppressors such as PTEN, 
and that these mutations arise early on during tumor progression (Negrini, Gorgoulis, 
& Halazonetis, 2010). These two observations make it highly improbable that 
mutations in caretaker genes can account for the genomic instability present in most 
sporadic tumors from very early stages of tumor development (precancerous lesions). 
Some years before these genome-wide analyses it had been shown both in vitro 
and in animal models that oncogene activation leads to DNA damage and 
activation of the DNA damage response (Abulaiti et al., 2006; Bartkova et al., 2006; 
Denko et al., 1994; Di Micco et al., 2006; Ray et al., 2006). Altogether, these data lead 
to the formulation of the oncogene-induced DNA damage model for cancer 
development (Fig 2). This model proposed that the first event of tumor development 
is the acquisition of an oncogenic mutation, which would lead to increased cell 
growth and proliferation promoting the appearance of precancerous lesions. The 
aberrant proliferation induced by oncogenes leads to replicative stress and DNA 
damage, thus activating the antitumorigenic activity of the DNA damage response 
and inducing apoptosis and senescence. However, the continuous induction of DNA 
damage promotes genomic instability favoring the acquisition of additional mutations 
that drive tumor progression releasing the cells from the DDR-imposed senescence 
and apoptosis (Halazonetis, 2009; Halazonetis, Gorgoulis, & Bartek, 2008).  
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Figure 2. Oncogene-induced DNA damage model for cancer development. Scheme 
depicting the main event in tumor development according to the oncogene induced DNA 
damage model for cancer development. Adapted from (Halazonetis et al., 2008).  
 
 
1.3. Oncogene-induced replication stress. 
The oncogene-induced DNA damage model for cancer development is based on 
the capacity of activated oncogenes to induce replication stress and generate DNA 
damage, but how do oncogenes actually lead to replicative stress?  
Replication stress is a complex phenomenon characterized by the presence of 
stalled, collapsed or other aberrant fork structures and a replication slowdown. It 
arises when the tight replication regulation, that ensures correct duplication of the 
DNA, is disrupted (Zeman & Cimprich, 2014). 
In order to ensure the correct replication of the DNA, this process has to be 
coordinated with cell cycle progression (Gaillard, García-Muse, & Aguilera, 2015). 
The first step of replication is origin licensing which consists of the assembly of pre-
replicative complexes (pre-RC) onto replication origins. The main component of the 
pre-RC is the minichromosome maintenance helicase (MCM), which is recruited, 
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along with other factors, during the G1 phase of the cell cycle. At G1/S transition high 
cyclin-dependent kinase 2 (CDK2) activity will activate the MCM triggering the 
replisome loading and origin firing. Through different CDK-dependent mechanisms, 
it is also ensured that origins can only be licensed once in each cell cycle. 
The presence of activated oncogenes has been shown to interfere with this regulation 
by different means (Hills & Diffley, 2014) (Fig 3).  
- Origin under-usage: origin licensing depends on a window of low CDK2 activity 
during G1 phase. However, several oncogenes induce cyclin E, a positive regulator 
of CDK2, overexpression. This causes a reduction in MCM helicase complex 
assembly, which leads to fewer origin firing. The replication checkpoint would 
normally prevent the entry into S phase of cells with reduced origin licensing but it is 
commonly compromised in cancer cells with deregulated E2F and p53 pathways.  
- Origin over-usage: the increased firing of dormant origins can promote genomic 
instability through the exhaustion of replication factors as deoxynucleotides. This leads 
to a reduction of replication speed and fork stalling. RPA exhaustion also promotes 
double strand break formation by leaving single-stranded DNA unprotected. 
Furthermore, an increased number of replicons can lead to the collision between 
transcription and replication inducing fork stalling and collapse.  
- Origin re-usage: Many of the factors that form the pre-replication complex are E2F 
targets, which is commonly upregulated in cancer. The upregulation of these pre-RC 
components may be the cause of the re-replication observed in human cells upon 
Ras or CycE overexpression. Origin re-usage may lead to increased active origin 
number leading to fork collision. Alternatively, excessive origins can cause the 
depletion of replication factors and cause fork slowdown or stalling.  
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Figure 3. Summary of oncogene induced DNA replication stress (Adapted from Hills & 
Diffley, 2014) . Oncogene activation can interfere with the regulation of DNA replication 
in various ways leading to origin over-usage, under-usage or re-usage causing the stalling 
or collapse of the replication forks thus promoting DNA damage and genomic instability.  
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2. The DNA damage response pathway 
2.1. The DNA damage response.  
Genomes are constantly subjected to sources of DNA damage both external as UV 
light or tobacco smoke and internal as replicative stress or ROS. In order to maintain 
genome stability and maximize organismal fitness, different mechanisms have 
evolved in order to cope with DNA damage. 
The DNA damage response is the group of cellular processes and pathways that 
aim to detect, signal and repair DNA damage or eliminate damaged cells. The way 
all of these events unfold will depend on the type of damage that is present (Fig 4).  
Upon single strand DNA breaks, the remaining strand is coated by the replication 
protein A (RPA) complexes, composed by 3 subunits RPA3, RPA70 and RPA2, 
protecting it from the action of nucleases that might further damage the DNA. RPA 
also promotes the ATRIP/mus304 mediated recruitment an activation of the ataxia 
telangiectasia related (ATR/mei41) protein kinase to ssDNA (Zou & Elledge, 2003). 
ATR becomes activated by autophosphorylation and goes on to phosphorylate the 
histone 2A variant (H2Av) ( Ward & Chen, 2001; Dekanty, Barrio, & Milán, 2015; Joyce 
et al., 2011) in order to amplify the damage signal to the DNA surrounding the 
original lesion, and to recruit the necessary proteins involved in DNA repair. 
Furthermore, ATR will phosphorylate and activate its downstream target Chk1 in order 
to induce a G2 cell cycle arrest (Bayer et al., 2018; de Vries et al., 2005) and allow 
time for DNA damage repair before cells enter into mitosis.   
In the presence of double strand breaks, the MRN complex composed of the meiotic 
recombination homolog (Mre11), the DNA repair protein Rad50 and the Nijmegen 
breakage syndrome protein 1 (Nbs1) binds to the DNA and acts as a damage 
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sensor. Subsequently, the MRN complex will recruit and activate the ataxia 
telangiectasia mutated (ATM/ Tefu) protein kinase through its interaction with the 
Nbs1 subunit (Syed & Tainer, 2018). Once activated, ATM will phosphorylate H2Av in 
order to amplify the damage signal and recruit the necessary factors for DNA repair 
(Joyce et al., 2011). ATM will also phosphorylate its downstream target Chk2 / Loki 
in order to promote p53 mediated apoptosis and DNA repair (Brodsky et al., 2004; 
Peters et al., 2002). 
 
 
Figure 4. Summary of the DNA damage response pathway. The DDR is responsible for 
detecting, signaling and repairing DNA damage as well as inducing apoptosis or 
senescence of severely damaged cells in order to maintain organismal fitness. It does so 
by the activation of a kinase cascade that leads to the activation and recruitment of all 
the necessary factors to promote the above-mentioned effects.  
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These two pathways that seem to be completely independent commonly act 
together. This is due to the fact that unrepaired ssDNA breaks can lead to the 
formation of dsDNA breaks through degradation of the DNA, fork collapse, mitotic 
segregation of under replicated DNA, etc. On the other hand, the presence of dsDNA 
breaks often leads to ssDNA as a repair intermediate after end resection.  
2.1.1. DNA damage repair pathways. 
After the damage has been detected, several DNA repair pathways come into play 
in order to repair the damage. Each repair pathways will deal with a different type 
of DNA damage and can be subdivided depending on whether they act to repair 
single or double strand damage (Chatterjee & Walker, 2017) (Fig 5).  
Double strand damage repair:  
- Homologous recombination. This pathway is used in order to repair double strand 
DNA breaks in the presence of a template DNA. This means that this mechanism 
can only be used during S and G2 phases of the cell cycle, where the genome has 
already been duplicated. This is a conservative mechanism that implies the resection 
of the damaged ends, a homology-directed strand invasion and finally DNA synthesis 
of the missing areas. 
- Non-homologous end-joining. This is an error prone pathway that is used to repair 
dsDNA breaks when a DNA template is missing. In this case, there will be a simple 
processing and re-ligation of the ends which can usually lead to inaccurate repair 
and short deletions.  
Single strand damage repair:  
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- Base excision repair. It is involved in the repair of lesions that arise from the 
modification of DNA bases by mechanisms such as oxidation or alkylation. The 
damaged base is removed by a glycosylase and the remaining abasic site is 
removed by endonucleases and replaced by DNA synthesis.  
- Nucleotide excision repair. This is a very important DNA repair mechanism since it 
is the one responsible for the repair of the bulky lesions induced by UV light. Once 
the damage is recognized, a segment containing the lesion is removed and the 
remaining strand serves as a template for DNA synthesis, and, finally, the ends are 
ligated. There are two forms of NER, global NER - that can act throughout the 
genome, and transcription-coupled NER - that is activated when the transcription 
machinery is blocked by the presence of a lesion 
 
Figure 5. Summary of DNA damage repair pathways. Adapted from (Corcoran et al., 
2016). dsDNA breaks are repaired via HR or NHEJ depending on the presence of a 
template or not. ssDNA breaks are repaired by different mechanisms depending on the 
type of damage that has been generated. Fanconi anemia pathway acts to repair inter-
strand crosslinks.   
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- Mismatch repair. It is the mechanism in charge of repairing the erroneous pairings 
of bases that can happen during replication. This mechanism is capable of detecting 
the parental strand and after resection of the incorrect base use it to repair the 
damage.  
- Fanconi anemia pathway. It is necessary for the repair of inter-strand crosslinks; 
these lesions cause a covalent bond between the two DNA strands leading to a 
blockade in replication and translation.  
2.2. The DDR and its implications in cancer. 
The DNA damage response (DDR) pathway has been shown to be activated early 
on in the tumorigenic process at precancerous stages and to act as an anticancer 
barrier, preventing the accumulation of mutations and the progression into more 
aggressive stages. In order for tumors to progress from benign to malignant, the DDR 
has to be inactivated and many times cells acquire mutations in key DDR genes. At 
the same time, tumor cells have a very highly proliferative which leads to replication 
stress and DNA damage. In these conditions, cells depend on the residual DDR 
activity in order to repair the damage and survive, leaving tumor cells hanging in a 
very tight equilibrium depending on the right amount of DDR pathway activity 
(Halazonetis et al., 2008).  
2.2.1. Exploiting the DDR to target cancer cells. 
Given the fragile situation of cancer cells, their dependency on the DDR and DNA 
repair in advanced stages could be used to selectively target cancer cells, either as 
a monotherapy in tumors deficient for some DDR proteins or in combination with 
radio- or chemotherapy as a sensitizer to DNA damage (Weber & Ryan, 2015).  
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A successful example of the use of this strategy is the use of PARP inhibitors to treat 
BRCA1 deficient tumors, which have impaired homologous recombination DNA 
repair. PARP proteins are involved in DNA repair via base excision repair. Their 
inhibition will lead to unrepaired DNA and subsequently, dsDNA breaks, which will 
not be repaired or not efficiently given that the cells lack proper homologous 
recombination thus leading to cell death (Tangutoori, Baldwin, & Sridhar, 2015).  
Even nowadays, the main treatment option for many tumors is the use of chemo- and 
radiotherapy as therapeutic agents that target rapidly dividing cells. An increasing 
number of studies are focusing on the search of synthetic lethal interactions between 
the generation of DNA damage by the use of genotoxic agents and the depletion 
of DNA damage repair genes (Helleday et al., 2008; O’Connor, 2015; Toulany, 2019).  
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3. Ras oncogene 
3.1. Discovery and function of Ras proteins.  
Ras research dates back to the ‘70s when rat sarcoma viruses were discovered. 
Shortly after they were shown to promote tumorigenesis through the presence, in the 
viral sequence, of rat genes, they were named Ras genes after rat sarcoma virus. In 
the early ‘80s first human Ras genes were found and shown to transform cells and 
to play a role in human pathogenesis (Malumbres & Barbacid, 2003).  
In mammals, there are three different Ras genes: H-Ras and K-Ras - identified from 
Harvey and Kirsten sarcoma viruses - and N-Ras -identified in neuroblastoma cell 
lines. Each of these genes seems to have slightly different activities and to be 
majoritarian in different tissues (Tsuchida et al., 2016). However, in Drosophila 
melanogaster there is only one Ras gene named Ras1 which shares a 75% 
homology with H-Ras (Neuman-Silberberg et al., 1984). 
Ras is one of the most commonly mutated oncogenes with Ras mutations being 
present in about one third of all human cancers. Different Ras oncogenes present a 
unique mutational signature; K-Ras mutations are most commonly found in pancreatic 
and colorectal tumors, while H-Ras and N-Ras are most common in salivary gland 
and skin tumors, respectively (Table 1).  
Table 1. Frequency of Ras mutation in human cancer.  
TISSUE KRAS HRAS NRAS Incidence Mortality 
Biliary tract 20% 1% 3%   
Cervix 6% 3% 1% 15 8,2 
Endometrium 15% 0% 2%   
Genital tract 7% 1% 2%   
Haematopoietic and lymphoid 5% 1% 9%   
Large intestine 33% 1% 4% 24 11,5 
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Lung 16% 0% 1% 27 23,1 
Ovary 13% 0% 1% 8  
Pancreas 55% 0% 1% 6 5,7 
Penis 8% 8% 3% 1 0,39 
Peritoneum 46% 0% 1%   
Salivary gland 2% 12% 1% 1 0,29 
Skin 3% 10% 15% 4 0,8 
Small intestine 24% 0% 1%   
Stomach 6% 1% 1%   
Thyroid 2% 4% 8% 7 0,54 
Upper aerodigestive tract 2% 5% 1%   
Urinary tract 6% 9% 2%   
Data on mutation frequency for the different Ras oncogenes comes from the COSMIC 
database. Data on mortality and incidence of each cancer type comes from the Global 
cancer observatory (GCO) an initiative of the international agency for research on cancer 
(WHO) and represents the rate per 100.000 cases.  
 
3.1.1. Ras activation and regulation. 
Ras proteins are small G proteins (guanine nucleotide binding proteins) that act as 
molecular switches conveying information from external stimuli into the cell. Ras 
proteins have two conformations: ON, when they are bound to GTP, and OFF, when 
they are bound to GDP (Simanshu, Nissley, & McCormick, 2017). Upon ligand binding 
to receptor tyrosine kinases such as EGF to the EGF receptor, the receptor dimerizes 
and becomes phosphorylated. This phosphorylation leads to the recruitment to the 
membrane of Son of sevenless (Sos), a guanine nucleotide exchange factor (GEF) 
that was originally discovered in Drosophila genetic screens (Rojas, Oliva, & Santos, 
2011). GEFs promote the ejection of GDP and its replacement with GTP, that is much 
more abundant in the cytosol, thus leading to Ras activation. On the other hand, Ras 
inactivation is mediated by GTPase activating proteins (GAP) which accelerate Ras-
mediated GTP hydrolysis (Fig 6).  
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The most common oncogenic Ras mutations are those found in the position 12 and 
13 of the protein and consist on aminoacid substitutions that prevent the proper 
interaction between Ras and GAP proteins, thus rendering Ras in a GTP bound state 
that is constitutively active. Also common are mutations in position 61 in the catalytic 
site of Ras resulting in impaired GTP hydrolysis (Pylayeva-Gupta, Grabocka, & Bar-
Sagi, 2011).  
 
Figure 6. Regulation of Ras activation and inactivation. Upon ligand binding the RTK 
receptor dimerizes and autophosphorylates recruiting the GEFs responsible of Ras 
activation. GAP proteins promote GTP hydrolysis and inactivation.  
 
3.1.2. Ras effectors and signaling pathways. 
Once Ras has been activated, several effectors can be recruited and activated 
leading to multiple outcomes ranging from proliferation, growth, differentiation to 
apoptosis among many others (Karnoub & Weinberg, 2008).  
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RAF kinase (Rapidly accelerated fibrosarcoma) was the first Ras effector to be 
identified. RAF activation is induced by its association to activated Ras, that recruits 
RAF to the membrane where it becomes phosphorylated and activated. RAF 
activation elicits a MAPK (mitogen activated protein kinase) kinase cascade where 
RAF phosphorylates and activates MEK which in turn activates ERK. ERK will 
phosphorylate several targets among which ETS and Fos transcription factors that 
will give rise to a plethora of cellular responses (Fig 7).  
 
 
Figure 7. Summary of the MAPK-ERK and PI3K signaling pathways. Downstream of Ras 
activation several effector pathways will be activated in order to give rise a diverse 
response. The main effector pathways are the ERK and the PI3K pathways. 
 
 
A year after RAF identification, PI3K (phosphoinositide 3 kinase) was found to drive 
responses downstream of Ras. PI3K can be directly activated via interaction with a 
phosphorylated RTK receptor but also it can become phosphorylated and activated 
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through its interaction with Ras. Once PI3K is activated, it phosphorylates 
phosphatidylinositol 4,5- bisphosphate (PIP2) into phosphatidylinositol 3,4,5- 
triphosphate (PIP3) which will activate AKT kinase.  AKT, in turn, phosphorylates and 
induce the dissociation of the repressor complex TSC1-TSC2, thus leading to mTORC 
activation (Fig 7).  
Ral (Ras like) and several other effectors have also been described. However, their 
implications on Ras malignancy and the mechanistic details of their downstream 
pathways are less clear than for the other two.  
3.2. Ras and the Hallmarks of cancer  
Oncogenic Ras activation has been shown to recapitulate many of the hallmarks of 
cancer. Among them Ras has been shown to have a prominent role in the induction 
of proliferation and the inhibition of apoptosis. Ras also promotes a metabolic shift 
from oxidative phosphorylation to aerobic glycolysis in order to more effectively 
produce the building blocks necessary for cell growth and division. This change is 
induced via the upregulation of the hypoxia inducible factor 1α mediated by mTOR. 
Ras can also participate in the remodeling of the microenvironment and the induction 
of angiogenesis via the expression of different cytokines and the vascular endothelial 
growth factor A (VEGFA). Also, Ras expression reduces the immunogenicity of cancer 
leading to the evasion of the immune response (Pylayeva-Gupta et al., 2011).  
3.2.1. Ras and cell cycle regulation. 
One of the main features of cancer is the promotion of proliferation independently of 
the presence of mitotic signals, as Ras is a key mediator of these signals it is not 
surprising that Ras activating mutations can drive proliferation. In mammals, it has 
been shown that Ras can promote the entry into the cell cycle of G0 arrested cells 
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by promoting the expression of the G1 cyclin D1 through the RAF and PI3K pathways. 
Cyclin D1 expression will lead to CDK2 activation and the phosphorylation of 
retinoblastoma that will then release E2F. Once E2F is activated, it will go to the 
nucleus and drive the expression of genes involved in G1/S transition such as cyclin 
E or PCNA (Downward, 1997).  In Drosophila a similar mechanism takes place; 
however, in this case, Cyclin D1 doesn’t seem to play a central role (Datar et al. 
2000). Instead, it is cyclin E the one upregulated to bind CDK2 in order to 
phosphorylate and inactivate retinoblastoma.  
3.2.2. Ras and apoptosis suppression. 
Ras has been shown to prevent proper apoptotic response and to promote cell 
death evasion, one of the main hallmarks of cancer. In mammals, this is 
accomplished by the upregulation of antiapoptotic genes and the downregulation of 
proapoptotic genes through both PI3K and RAF pathways (Cox & Der, 2003). Besides 
its prominent pro-survival function, Ras has also been shown to elicit some 
proapoptotic responses for example through the MAPK-mediated activation of the 
JUN N-terminal kinase signaling. The capacity of Ras to induce tumorigenesis 
suggests that its pro-survival role prevails. In Drosophila, Ras prevents apoptosis via 
the inhibition of the pro-apoptotic gene hid. Hid (Smac/Diablo in mammals) is 
blocked downstream of the RAF-MAPK signaling pathway and two mechanisms of 
inhibition have been proposed. On the one hand, it was proposed that ERK can 
directly phosphorylate and inhibit hid (Bergmann et al., 1998); on the other hand, it 
was suggested that ERK through an ETS transcription factor can downregulate hid 
expression (Kurada & White, 1998).  
Introduction 
 
 
39 
3.4. Ras drug strategies 
Given the prevalence of Ras mutations in cancer, many efforts have been made in 
order to find ways to target Ras mutant cancer cells. However, although many 
strategies were promising, none of them has proven clinically relevant. This has led 
to the general conception that Ras is an undruggable oncogene. Over the years, 
several approaches were used in order to tackle this problem (Cox et al., 2014) (Fig 
8).  
- Direct Ras inhibition. The main problem of this approach is the fact that most Ras 
mutations destroy Ras enzymatic activity as a GTPase, and bringing and enzymatic 
activity back is practically impossible. To circumvent this problem, several groups 
have worked in the design of small molecules that can interfere with Ras binding to 
GTP, SOS1, RAF, etc. Unfortunately, none of them has made it into the clinic so far.  
- Blocking Ras membrane localization. Ras proteins need to localize to the 
membrane in order to exert their function. Several posttranslational modifications 
allow the membrane localization of Ras. Inhibitors of the enzymes responsible for 
such modifications exist and have been tested, however in the cases they do work 
they have many other target proteins that complicate their therapeutic use.  
- Inhibiting Ras effectors. RAF-MEK-ERK cascade is one of the main effector pathways 
of Ras. This is a complex pathway that has negative feedback loops in order to shut 
down the pathway. Thus, a negative effect of the inactivation of the kinases might be 
an upregulation of the upstream signaling thus rendering the inhibitor useless. 
Nevertheless, two RAF inhibitors (Vemurafenib and Dabrafenib) and one MEK 
inhibitor (Trametinib) are efficient enough and have been FDA approved for the 
treatment of BRAF mutant metastatic melanomas. Another issue with these inhibitors 
is the emergence of resistance by upregulating the pathway downstream.  PI3K 
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inhibitors are also under clinical evaluation however they have rendered rather 
disappointing results against Ras mutant tumors.  
- Synthetic lethal interactions. This strategy is particularly interesting for cases like the 
Ras oncogene that cannot be directly targeted.  Synthetic lethal screens are based 
on the identification of genes that are essential for the survival of tumor cells but not 
for normal cells. Original screens were performed by short hairpin mediated 
depletion and lead to the identification of several therapeutic targets (Downward, 
2015). However, in the past few years, the approval of MEK inhibitors has prompted 
the implementation of chemical-based screens in which combinations of drugs are 
tested. This method has been successful in identifying synthetic lethal drug 
combinations that are now under clinical evaluation (Pang & Liu, 2017).  
 
Figure 8. Strategies for targeting Ras mutant tumors. Different approaches have been 
used in the search for therapies that selectively target Ras mutant tumors. On the one 
hand inhibitors that affect Ras signaling at different levels.  On the other hand, the search 
for synthetic lethal interaction that impinge on cellular mechanisms that help cells cope 
with oncogenic stress, thus offering a selective target. Adapted from (Cox et al., 2014). 
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4. Drosophila as a model organism 
4.1. Drosophila melanogaster in research. 
Drosophila melanogaster is a versatile model organism that has been used for over 
a century in very diverse areas of study. At the beginning of the20th century, Thomas 
Hunt Morgan introduced Drosophila into his laboratory making seminal contributions 
to the genetics field. Among them, improving Mendel’s inheritance theories, 
demonstrating that genes were found in chromosomes (Bellen, Tong, & Tsuda, 2010).  
Although for the first part of the century Drosophila was primarily used in genetic 
studies, its worth as a model organism has not been limited to it, as shown by the six 
novel prices in physiology that have been awarded to investigations conducted with 
this organism (Fig 9). This is due to the fact that genes involved in basic cellular 
processes and signaling pathways are conserved throughout evolution. Indeed, After 
the sequencing of its genome in the year 2000, it was found that 75% of disease-
related genes in humans are conserved in Drosophila, consolidating it as a model 
for biomedical research. This together with the fact that it is a much simpler, yet in 
vivo model makes Drosophila the perfect system in which to study gene function. 
Drosophila is a highly amenable organism for genetic manipulation, which for many 
years has been one of the main advantages of its use over other model organisms. 
The capacity to generate and maintain new mutant stocks combined with protein 
expression systems that allow for a tissue specific and temporally controlled 
expression of desired genes and constructs has made Drosophila a great organism 
to study basic gene functions (Hales et al., 2015). In fact, many genes involved in the 
most relevant signaling pathways were first identified in Drosophila.  
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Other, more general, characteristics that make of Drosophila the perfect model 
organism are its high breeding capacity and short life cycle, its simple genome with 
only 4 chromosomes and low redundancy, the relatively low maintenance cost or the 
capacity to perform in vivo studies.  
 
Figure 9. Nobel prizes in medicine and physiology awarded to Drosophila research. 
For many years researchers have worked in Drosophila genetics and the production of 
new mutants and tools to investigate gene function. More recently the Drosophila genetic 
toolkit has been used to discover new genes involved in physiologically relevant cellular 
and organismal processes. 
 
4.2. Drosophila development  
Drosophila is a holometabolous insect: it presents 4 different life stages (egg, larva, 
pupa and imago) and goes through a metamorphosis process during its 
development. At 25ºC the entire development of a fly takes around 10 days. For the 
first day, the embryo develops inside the egg before hatching in the form of a first 
instar larvae. For the next four days, the larvae eat and grow through three different 
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molds until they reach the appropriate size, pupariate and enter into metamorphosis 
(Fig 10). During this process, most of the larval tissues are destroyed while the so-
called imaginal tissues are remodeled in order to give rise to the proper adult 
structures (Jennings, 2011).   
During larval stages, we can find two types of tissues. On the one hand, larval tissues, 
that grow by endoreplication giving rise to polyploid tissues that form the biggest 
part of the larvae. On the other hand, imaginal tissues, which are specified during 
embryonic development, start out as very small groups of cells and rapidly divide 
during larval stages. After metamorphosis, imaginal tissues give rise to the structures 
of the adult body. 
Figure 10: Schematic of Drosophila life cycle. During its life cycle Drosophila goes 
through different stages. First the embryo develops for one day before it hatches into a 
first instar larva after two more larval stages, the pupae is formed and metamorphosis 
take place before new adults arise. Extracted from (Ong et al., 2015).  
 
In this work, I have used both wing and eye-antenna imaginal discs. The wing 
imaginal disc is subdivided along the anterior-posterior and dorsal-ventral axis into 
different compartments, which are comprised by cells that will not intermingle and 
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that have specific expression patterns of developmental genes that can be used as 
tissue specific drivers for gene expression.  
During this work, I have taken advantage of the dual GAL4/UAS transactivation 
system. Coming, originally, from yeast, it was introduced in Drosophila by Andrea 
Brand and Norbert Perrimon (Brand & Perrimon, 1993). This system allows us to 
express any gene or RNAi of interest in specific areas of the wing disc. Together with 
the temperature sensitive repressor GAL80ts, it also allows for a temporally controlled 
expression of the transgene. I have also used the MARCM technique in order to 
induce labelled mitotic clones were we can control gene expression (Lee & Luo, 
1999) .  
4.3. Drosophila cancer models  
The first report of Drosophila being used to study a cancer related phenotype dates 
as back as 1916, when Mary Stark, a PhD student in Morgan's lab, described the 
black granules that were caused by the lethal 7 factor. Years later it was discovered 
that the granules were actually melanotic tumors. Since then, many oncogenes and 
their molecular functions have been discovered by using this model organism. This 
happened even before their link to cancer was known, making a strong point for the 
need of basic research. It is the case of some of the most preeminent oncogenes in 
cancer such as Notch, hedgehog, hippo or JAK/STAT. For other oncogenes that were 
not discovered in Drosophila, such as Ras, research performed in Drosophila has 
been crucial to delineate its signaling pathways (Beira & Paro, 2016). 
Based on this knowledge and despite the limitations of Drosophila (lack of some 
human tissues and organs, open circulatory system, lack of adaptive immunity), 
several cancer models have been established that recapitulate many of the 
hallmarks of cancer, such as: resistance to cell death, sustained proliferative 
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signaling, genome instability and mutation, invasion and metastasis, reprogramming 
cellular metabolism and inflammation (Gonzalez, 2013; Rudrapatna, Cagan, & Das, 
2012).  
4.3.1. Ras oncogene dependent Drosophila cancer models 
Among the Drosophila cancer models that exist, some of the most commonly used 
are those based on the presence of a constitutively active version of the Ras 
oncogene.  
The first ones to evaluate the effects of RasV12 constitutively active mutant expression 
in the wing imaginal discs were Karim and Rubin in 1998. They showed that RasV12 
expression in the eye and wing imaginal discs was capable of inducing proliferation 
and tissue hyperplasia and that MAPK signaling was necessary but not sufficient to 
induce this effect (Karim & Rubin, 1998). Two years later, Edgar and Prober went 
deeper into the regulation of RasV12-induced proliferation. By using RasV12 clones, 
they showed that RasV12 induces cell growth and G1/S transition by upregulating 
the proto-oncogene dMyc and CycE (Prober & Edgar, 2000).  Furthermore, they 
showed that RasV12 can also activate PI3K signaling and that PI3K activity promotes 
cell growth and G1/S transition (Prober & Edgar, 2002).  
Rarely, tumors arise from a single mutation. More commonly, they are the result of a 
multistep process in which cells accumulate mutations that provide the cells with the 
necessary characteristics to induce tumor formation. In 2003, Brumby and Richardson 
showed the first example of cooperative tumorigenesis in Drosophila. They took 
advantage of the MARCM system to induce scribble mutant clones that also express 
RasV12. While scribble mutant clones die by JNK induced apoptosis, in RasV12, 
scribble mutant clones cell death is prevented and the clones overgrow to a much 
larger extent than RasV12 alone clones (Brumby & Richardson, 2003). In that same 
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year, Pagliarini and Xu introduced Drosophila as a model to study metastatic 
behavior. They performed a genetic screen and identified the cooperation between 
RasV12 and scribble mutation to induce invasion of adjacent organs and migration 
to distant sites. Both behaviors depend on the decrease in E-cadherin levels. 
Furthermore, they observed that RasV12, scribble mutant cells degrade the basement 
membrane and upregulate the actin cytoskeleton at the migration sites (Pagliarini & 
Xu, 2003). The same group demonstrated that the JNK proapoptotic signal, induced 
by the loss of the polarity determinant scribble,  is switched to a pro-tumorigenic role 
in the presence of RasV12 and that this signal is necessary and sufficient to induce 
the invasion and migration of the RasV12 cells (Igaki, Pagliarini, & Xu, 2006). At the 
same time, it was shown that the pro-tumorigenic role of JNK needs of a dFos 
dependent transcriptional activation of the matrix metalloprotease MMP1 (Uhlirova 
& Bohmann, 2006).   
Tumors are comprised of heterogeneous cell populations both genetically and 
functionally. Drosophila Ras models have been used to monitor the tumorigenic 
interactions between different clonal populations. In 2010, it was shown that RasV12 
and scribble mutant clones could cooperate to promote tumor growth and invasion 
(Wu, Pastor-Pareja, & Xu, 2010). It was also shown that RasV12 clones carrying 
mitochondrial defects can non-autonomously induce the growth and invasion of 
RasV12 clones through the expression of mitogenic molecules (Ohsawa et al., 2012). 
Another example on intratumor cooperation is that shown by Marco Milan’s lab in 
which we demonstrated that delaminated cells from the tumor express mitogenic 
molecules in order to drive the unlimited growth of the non-delaminated cells of the 
same tumor (Muzzopappa, Murcia, & Milán, 2017).  
Tumor growth can also be affected by the interactions with its microenvironment. A 
very nice example of this crosstalk between the tumor and its microenvironment is 
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that of autophagy. While it was shown that tumor autonomous autophagy could 
suppress tumorigenesis by preventing the accumulation of reactive oxygen species 
(Manent et al., 2017), it was also shown that non-autonomous autophagy had the 
opposite role and was fueling tumor growth by providing nutrients to the tumor 
(Katheder et al., 2017). Understanding this type of interactions is crucial when 
considering possible therapeutic cancer targets.  
Tumors have been shown to interact with the immune system.  However, the role of 
immune cells in tumor growth is not clear yet. Drosophila RasV12, Scribble mutant 
tumors have been used to study the role of the immune system in tumor growth.  First, 
it was proposed that hemocytes (Drosophila macrophages) are recruited to tumor 
sites in order to prevent growth and invasion by depositing collagen to counteract 
the basement membrane degradation (Pastor-Pareja, Wu, & Xu, 2008).  Hemocytes 
were also proposed to promote tumor growth by inducing JNK signaling through the 
ligand TNF (Eiger In Drosophila, (Cordero et al., 2010)). However, later on, it was 
demonstrated that while they are recruited, hemocytes do not seem to play a major 
role in tumor growth (Muzzopappa et al., 2017).  
Not only short range microenvironmental interactions are relevant for tumor 
progression but also less understood long-range systemic interactions play a role. 
Cachexia is a phenomenon that leads to weight loss and muscular atrophy and is 
an indicator of poor prognosis in cancer. Flies carrying RasV12 scribble mutant 
tumors have been used to study cachexia since they present similar wasting 
phenotypes. It was shown that the tumors secreted Impl, an antagonist of insulin 
signaling thus promoting insulin resistance in peripheral tissues (Figueroa-Clarevega 
& Bilder, 2015).  
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In the era of genomic data and personalized medicine, Drosophila is being used as 
a screening platform for the search of new treatment opportunities for RasV12 
dependent tumors (Kasai & Cagan, 2010; Levine & Cagan; 2016; Willoughby et al., 
2013).  
RasV12-dependent tumors in Drosophila have been shown to present several 
hallmarks of human cancer such as sustained proliferative signaling, resistance to 
cell death or invasion and metastasis (Fig 11). Furthermore, except for angiogenesis, 
all other hallmarks of cancer can be studied in these Drosophila models.  
 
Figure 11. Schematic summary of the characteristics of RasV12 and RasV12, scrib-/- 
tumors. In green tumor cells, in gray adjacent epithelial wild type cells and in blue the 
basement membrane of the epithelium. Thick arrows represent the different interactions 
that the tumor cells can engage. Thin arrows represent the tumor intrinsic behavior.  
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Objectives 
Despite our increasing understanding of the biology of cancer cells, Ras has been 
nicknamed as the undruggable oncogene due to the difficulty of finding therapies 
that are both safe and effective. Oncogenes have been proposed, through the 
induction of aberrant proliferation, to induce replicative stress which in turn can lead 
to genomic instability and mutation, a driving force for tumor progression. In that 
regard, we took advantage of Drosophila, as a well-established model organism, to 
accomplish the following objectives:  
- To reanalyze the capacity of Ras oncogene to promote cell cycle 
progression.  
- To evaluate the induction of DNA damage and replicative stress caused by 
Ras. 
- To study the relationship between Ras and the DNA damage response 
(DDR) pathway. 
- To investigate the role of MAPK-ERK pathway in blocking apoptosis in tumors 
and homeostatic situations.  
- To use the previous results to design and test genetic as well as chemo- and 
radiotherapies to selectively target Ras-expressing cells.  
Tumors are formed by heterogeneous cancer cell populations but also by other cells 
like fibroblasts, immune cells or normal tissue cells that communicate with the tumor 
and contribute to tumor growth. Tumor microenvironment has emerged as a very 
crucial regulator of tumor growth and for that reason, we decided to set the following 
objectives.  
Objectives 
 
 
 
52 
- To analyze the effect of Ras on adjacent wild type epithelial cells.  
- To evaluate the contribution of these cells to tumor growth.  
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1. Characterization of RasV12 effects on tissue growth and 
cell cycle. 
As has been described in the introduction, one of the main functions of Ras 
oncogenes is to promote cellular proliferation. In this chapter, we have analyzed the 
impact of the expression of a constitutively active form of Ras, RasV12, in promoting 
proliferation and tissue growth. We have also analyzed the cell cycle changes 
derived from this expression. In order to do that we have used the Gal4/UAS system 
to express RasV12 in specific compartments of the wing disc. Given the lethality of 
early expression of RasV12, we used the Gal80ts repressor and kept the larvae for 
6 days at the restrictive temperature of 18ºC and then shifted them to 29ºC to allow 
transgene expression for three days, unless stated otherwise.  
1.1 RasV12 expression promotes G1/S transition and tissue 
overgrowth.  
Expression of RasV12 in the dorsal compartment of Drosophila wing imaginal discs 
leads to overgrowth and folding of the tissue (Karim & Rubin, 1998) and (Fig 1 A, B 
and quantification in C). The apico-basal polarity of the tissue is not lost and E-
Cadherin is not miss-localized (Fig 1A’, B’). Moreover, there is only a weak expression 
of MMP1 (fig 1 B), a matrix metalloprotease that has been linked to epithelial to 
mesenchymal transition and malignancy (Uhlirova & Bohmann, 2006). This growth is 
considered hyperplasic since there are no signs of malignancy. 
RasV12 expression has been shown to drive G1/S transition in order to promote 
proliferation (Prober & Edgar, 2000). We confirmed previous reports by performing a 
DNA content analysis by FACS (fluorescence associated cell sorting) coupled with 
EdU (5-ethynyl-2 -´deoxyuridine) staining to label S phase cells.  We observed a shift 
in the DNA content profile from G1 towards G2/M. In control discs, 28% of the cells 
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are in G1, 23% in S and 49% in G2/M. Upon RasV12 expression, the number of cells 
in G1 drops to 17% while the cells in G2/M increase to 77% (Fig 2A). 
 
Figure 1. RasV12 promotes tissue overgrowth.  (A,B) Drosophila wing imaginal discs 
expressing the UAS-myrT and UAS-RasV12 transgenes under the control of the ap>gal4 
driver and stained for DAPI (Blue) and MMP1 (Green). Magnifications of this same discs 
show DAPI and MMP1 in gray. (C) Quantification of the disc area relative to the mean 
control size. (A’,B’) Cross-sections of RasV12 and wild type discs showing E-cadherin 
(green and gray) and DAPI (Blue).  
 
 
We obtained similar results when we analyzed the cell cycle by Fly-FUCCI, a 
fluorescently tagged degron based technique that allows for visualization of the 
different phases of the cell cycle. It depends on the degradation or not of the E2F 
Results 
 
 
57 
and CycB degrons tagged to GFP and RFP respectively (Zielke et al., 2014). As a 
proof of principle, in wild type discs, we can capture the developmentally 
programmed G1 and G2 arrest that occurs in the zone of non-proliferating cells 
(O’Brochta & Bryant, 1985).  When we quantified the asynchronously dividing wild 
type cells, 33% of the cells were in G1. However, when we expressed RasV12 this 
percentage dropped to 13%. This was accompanied by an increase in the amount 
of G2 cells that went from 40% in wild type to 79% in RasV12 cells (Fig 2B).  
 
Figure 2. RasV12 expression promotes G1/S transition. (A) EdU labelled FACS sorted 
cells expressing the myrT and RasV12 transgenes under the control of the apterous gal4 
driver to visualize the different phases of the cell cycle based on the DNA content, G1 
(green), S (red) and G2/M (yellow). (B,C,D) third instar wing imaginal discs expressing 
different transgenes under the control of the ap or hh gal4 drivers. B wing discs carrying 
the fly-FUCCI construct (ub-GFP-E2F11-230 and ub-mRFP1-NLS-CycB1-266) labelling the 
different phases of the cell cycle G1 (green), S (red) and G2/M (yellow). (C-D) Discs 
stained for cyclin E (C) and the E2F reporter PCNA-GFP (D) both in green and white.  
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Concomitantly, we observed an increase in the levels of the G1 cyclin E (Fig 2C) and 
the E2F target PCNA (Fig 2D), both involved in the induction of G1/S transition. We 
also observed increased levels of the mitotic cyclins E and A (Fig 3A-B), consistent 
with the increased amount of G2 cells and a possible G2 arrest.  
1.2 RasV12 and senescence.  
In mammals, it has been shown that oncogene induction can lead to replicative 
senescence (Di Micco et al., 2006). Furthermore, previous reports in Drosophila have 
shown that RasV12 expressing cells, in the eye-antenna imaginal discs, show some 
senescence features (Nakamura, Ohsawa, & Igaki, 2014) such as increased cell size, 
increased B-galactosidase activity and cell cycle arrest.  
In agreement with a senescent phenotype, during our analysis of the cell cycle, we 
noticed not only a shift from G1 to G2 but also a decrease in the number of 
replicating cells marked by EdU staining in the FACS analysis (Fig 2A in red). We 
observed a similar decrease when analyzing the Fly-FUCCI results (Fig 2B in red). 
Consistent with this, we observed low levels of replicating cells after 3 days of RasV12 
expression (Fig 3C), but not after 15 hours (Fig 3D) of expression. 15 hours of RasV12 
expression were sufficient to induce ERK phosphorylation (Fig 3 E, F). These results 
indicate that, somehow, RasV12 cells accumulate problems over time that hinder 
their replication and promotes a G2 arrest or elongation.  
Furthermore, we performed a gene set enrichment analysis on RNA-seq data of wild 
type and RasV12 wing discs. We found an expected positive enrichment in receptor 
tyrosine kinase (RTK) signaling that serves as a positive control of Ras signaling. 
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Figure 3. Oncogenic Ras and senescent phenotype. (A-F, H-I) wing imaginal discs 
expressing the indicated transgenes under the control of the ap-gal4 driver (A-D) or the 
en-gal4 driver (E-F, H-I) during 3 days (A,B,D,H,I) or 15h (C,E,F). Discs were stained for DAPI 
in blue, cycB in green and white (A), cycA in green and white (B), Edu in green and white 
(C-D), pERK in green and white (E-F), ß-gal in green and white (A), myrTomato (A-D) and 
Ci (E-F, H-I) both in red. (G) Enrichment plots for two significant GO terms ,positively 
enriched( RTK signaling) and negatively enriched (DNA replication). (J) (A) FACS sorted 
cells expressing the myrT, RasV12 (gray) and myrT, RasV12, String (black) transgenes 
under the control of the ap-gal4 driver to visualize the different phases of the cell cycle 
based on the DNA content. 
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More importantly, we also found a negative enrichment in the DNA replication class 
(Fig 3G). These results agree with the possibility that sustained RasV12 expression 
leads to DNA replication stress and senescence. Accordingly, we found slightly 
increased ß-gal activity in RasV12 expressing cells (Fig 3H, I).   
Finally, the G2 arrest induced by RasV12 expression could be rescued by String 
phosphatase (Cdc25) overexpression (Fig 3J), suggesting that these cells are, indeed, 
arrested in G2 by a String-dependent mechanism.  
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2. Evaluation of the RasV12 effects on the DNA damage 
response. 
The presence of activated oncogenes, as a response to the deregulated entry into S 
phase, has been shown to induce replicative stress which is one of the main sources 
of DNA damage and genomic instability (Hills & Diffley, 2014). In response to DNA 
damage, either single or double strand breaks, the DNA damage response pathway 
becomes activated in order to maintain the integrity of the DNA. It does so by eliciting 
different responses like the repair of the damage, the induction of a G2 arrest or the 
induction of senescence and apoptosis of the severely damaged cells (Song, 2005).  
2.1 RasV12 expression generates DNA damage. 
In mammals, it has been shown that RasV12 cells suffer from replicative stress and 
present signs of DNA damage due to the role of Ras in inducing G1/S transition. 
Previous reports in Drosophila suggested the opposite (Nakamura et al., 2014). 
Therefore, we decided to investigate the presence of replicative stress and DNA 
damage in Drosophila wing imaginal discs.  
We analyzed RPA3:RFP fusion protein, known to bind single stranded DNA and 
widely used as a replicative stress marker. We observed an increase in the intensity 
of the signal as well as foci formation at the sites of damage (Fig 4A), indicating that 
RasV12 cells suffer from replicative stress.  
Moreover, we analyzed Mre11 and Rad50, components of the MRN complex known 
to bind to and signal double stranded DNA breaks. Again, we observed an increase 
in the intensity as well as the formation of Mre11 and Rad50 foci at the sites of 
damage (Fig 4B, C).  This double stranded DNA breaks may be a consequence of 
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the resolution of stalled replication forks or of miss segregation of the chromosomes 
due to under-replicated DNA.  
 
 
Figure 4. RasV12 expression generates DNA damage. (A-C) Third instar wing imaginal 
discs expressing RasV12 under the control of the hh-gal4 driver and carrying different dna 
damage fusion proteins, (A) RPA-GFP in green, (B) Mre11-GFP in green and (C) Rad50-
GFP in red. Discs were stained for DAPI in blue and Ci in magenta, cells from the anterior 
compartment were used as a wild type control. (D) Mitotic pH3 (green or white) labelled 
cells from wing discs expressing GFP-i and RasV12 under the control of the ap-gal4 driver 
showing DNA bridges in RasV12 (white arrow). The percentage of chromosome bridges 
in RasV12 expressing cells (0,82±0,13; n=38) is significantly higher (p<0,001) than the one 
observed in wild type cells (0,096± 0,03; n=34). (E) Individual cells expressing GFP-i or 
RasV12 under the control of the ap-gal4 driver and subjected to comet assay. (F) scatter 
plot shows the tail moment (%Tail DNA x Tail Length) of over 200 cells per condition, GFP-
I in black and RasV12 in blue.  
 
 
Furthermore, we used the comet assay, a single cell electrophoresis technique that 
allows for direct DNA breaks visualization. We performed the comet assay in alkaline 
conditions thus detecting both single and double strand breaks. We observed an 
increase in the comet tail moment in RasV12 cells, reflecting increased DNA damage 
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(Fig 4E, F). This measurement is a combination of the length of the DNA tail that is 
formed, as well as the intensity of the tail which is a proxy of the amount of DNA.  
In RasV12 expressing discs, we found a range of mitotic defects from lagging 
chromosomes, DNA bridges to uncondensed DNA, all of them signs of DNA damage 
and replicative stress. We closely monitored the presence of DNA bridges (Fig 4D) 
which is 10 times higher in RasV12 cells than in wild type although its frequency is still 
relatively low.  
2.2 RasV12 blocks DNA damage signaling. 
The most commonly used way to mark DNA damage is the phosphorylation of the 
histone 2 variant (H2Av), the only homologue in Drosophila of the mammalian histone 
variants H2AX and H2AZ.  
Although we have seen that RasV12 cells carry high amounts of DNA damage (Fig 
4), we couldn’t detect any increase in H2Av phosphorylation in these cells (Fig 5A). 
Given this surprising result, we decided to challenge the cells with ionizing radiation, 
which is known to induce DNA double strand breaks and pH2Av marks. When we 
irradiated RasV12-expressing discs we could not detect any increase in H2Av 
phosphorylation (Fig 5B). These data, together with the fact that we observe 
recruitment of the early sensors of damage (Fig 4A-C), suggest that RasV12 might be 
acting at the level of the ATM and ATR kinases to impair the DNA damage response.  
In Drosophila ovary cells, both ATM and ATR kinases have been shown to 
phosphorylate H2Av upon activation (Joyce et al., 2011). Indeed, when we deplete 
ATM or ATR in otherwise wild type wing imaginal discs and we irradiate them, 
producing DSBs, there is a decrease in H2Av phosphorylation (Fig 5D) similar to that 
observed in RasV12 cells (Fig 5B).  
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Figure 5. RasV12 and H2Av phosphorylation. (A,B,D) Drosophila wing imaginal discs 
expressing the different transgenes under the control of the hh-gal4 driver. Discs were 
stained with DAPI (blue), Ci (red) and pH2Av (green and white). (B,D) Discs were X-ray 
irradiated with a 40Gy dose and dissected 5 hours afterwards. (C) Quantification of A 
and depicting the amount of pH2Av positive cells per area, GFP-I in grey and RasV12 in 
green. 
 
 
Then we decided to test if the lack of H2Av phosphorylation could be a trivial 
consequence of the depletion in H2Av levels. In order to do that, we overexpressed 
H2AV under its endogenous promoter or under the control of the GAL4/UAS system. 
In RasV12 discs co-expressing H2Av we did not observe any increase in pH2Av cells 
(Fig 6A, C). Upon irradiation of these discs, we could only detect a slight increase in 
H2Av phosphorylation in the case of the GAL4 driven expression of H2Av (Fig 6B, C). 
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Excluding the possibility of a general H2Av downregulation, the mechanism by which 
RasV12 cells regulate ATM and/or ATR activity remains still unresolved.  
 
Figure 6. Histone 2A variant levels and phosphorylation. (A,B) Third instar wing discs 
expressing the indicated transgenes under the control of the hh-gal4 driver. His2Av 
transgenes are labelled in red with either mKO or mRFP, discs were stained for DAPI 
(Blue) and pH2AV (green and white). (B) Discs were X-ray irradiated with a 40Gy dose 
and dissected 5 hours afterwards. (C) Quantification of A and B depicting the amount of 
pH2Av positive cells per area, RasV12 controls in grey and RasV12 together with the 
his2Av transgenes in green.  
 
2.2.1. RasV12 effects on checkpoint recovery. 
After the DNA damage response has been activated, and it has fulfilled its function 
to block the cell cycle and allow for DNA repair, it has to be switched off in order to 
resume normal cell dynamics. This is a tightly regulated mechanism that depends on 
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the expression of different phosphatases that will dephosphorylate and inactivate 
several DDR proteins such as ATM, ATR or H2AV.  However, it has also been shown 
that tumor cells can undergo checkpoint adaptation and resume cell cycle without 
resolving the DNA damage (Wang et al., 2015).  
It is possible that RasV12 cells are undergoing a checkpoint adaptation process, thus 
explaining the lack of H2Av phosphorylation. In order to test this possibility, we 
depleted several known checkpoint phosphatases in RasV12 discs and analyzed its 
effect on H2Av phosphorylation. When we removed different subunits of protein       
 
Figure 7. RasV12 and Checkpoint recovery kinases. (A) Third instar wing imaginal discs 
expressing the indicated transgenes under the control of the en-gal4 driver and stained 
for GFP (green), DAPI (blue) and pH2AV (red and white). Yellow lines outline the area of 
the posterior compartment. (B) Bar graph showing the quantification of the number of 
pH2Av positive cells in the posterior area.  
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phosphatase 2A or protein phosphatase 2C, we could not find any increase in H2AV 
phosphorylation (Fig 7A-B), suggesting that if there is checkpoint adaptation in 
RasV12 cells, it is not happening through any of these phosphatases. Depletion of 
Greatwall, a kinase involved in checkpoint adaptation, did give rise to increased 
pH2Av marks (Fig 7A-B). Unfortunately, that same effect was observed in wild type 
discs, discarding that the effect is specific for RasV12 cells.  
2.3 RasV12 impairs the DNA damage response function. 
Upon single stranded DNA breaks, RPA is recruited and ATR becomes 
phosphorylated and activated.  Upon ATR activation, its target Chk1 is 
phosphorylated and activated to promote a G2 cell cycle arrest and allow for DNA 
repair (Bayer et al., 2018a).  
Given the lack of ATM/ATR dependent H2Av phosphorylation, we decided to check 
for the activation status of ATR in RasV12 expressing tissues. In order to do that, we 
irradiated RasV12 and wild type tissues and measured the extent of the cell cycle 
arrest by counting the number of mitotic cells 5 hours after irradiation. The mitotic 
index in wildtype irradiated wing discs was clearly reduced when compared to non-
irradiated wild type tissues (Fig 8A, C). However, in the case of RasV12 discs, this 
reduction in the mitotic index did not happen (Fig 8B, C), suggesting that the ATR 
mediated cell cycle arrest is impaired in RasV12 tissues.  
Furthermore, when we expressed RNAi against ATR and Chk1 and irradiated the 
tissues, we observed a lack of an arrest in G2 similar to what we observe in RasV12 
(Fig 8D).  
Results 
 
 
 
68 
 
 
Figure 8. RasV12 and DNA damage induced cell cycle arrest. (A,B,D) Third instar lave 
wing discs expressing the indicated transgenes under the control of the hh-gal4 driver. 
Discs were stained for DAPI (blue) and pH3 (green and white). Discs in B and D were 
irradiated with a 40Gy dose and dissected 5h after. (C) Quantification of the amount of 
pH3 positive cells per area of A and B. Non-irradiated controls in gray and irradiated 
discs in green.  
 
Given the fact that many of the RasV12 expressing cells are already in the G2 phase 
of the cell cycle, we wanted to discard the possibility that this arrest is a consequence 
of DNA damage and ATR/Chk1 activation. In order to do that, we expressed RNAi 
against mei-41/ATR and grapes/Chk1 together with RasV12, we dissociated the cells 
and FACS sorted them to analyze the cell cycle by DNA content analysis. In none of 
the cases did we observe an alleviation of the G2 arrest (Fig 9), indicating that it is 
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not dependent on ATR/Chk1. This is consistent with the previous results that indicate 
that ATR is blocked in RasV12 cells.  
 
Figure 9. RasV12 G2 arrest is not dependent on ATR/Ch1 signaling.  FACS sorted cells 
expressing the indicated transgenes under the control of the ap-gal4 driver, cells were 
selected based on myrTomato expression. Cell cycle analysis was performed according 
to DNA content labelled with DAPI.  
 
 
2.5 Interaction between RasV12 and the DNA repair pathways. 
We have shown that RasV12 cells have high levels of DNA damage derived from 
the replicative stress they suffer.  We have observed both single and double strand 
breaks. DNA double strand breaks are normally recognized by the DDR and 
repaired by homologous recombination or non-homologous end joining depending 
on the phase of the cell cycle and the presence of a homologous template. However, 
we have observed that RasV12 cells present a deficient DNA damage response 
which leads to a deficient DNA repair.  Considering the amount of damage that they 
carry, we wondered whether RasV12 cells may be dependent on other DNA 
damage repair pathways in order to cope with the presence of unresolved DNA 
breaks.   
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In order to test this possibility, we performed an RNAi screen for genes involved in 
the main DNA repair pathways, homologous recombination, non-homologous end 
joining, base excision repair, nucleotide excision repair, mismatch repair and the 
Fanconi anemia pathway each one of them involved in the repair of different types 
of DNA damage. Since H2Av phosphorylation is not a good proxy to DNA damage 
in our case, we decided to evaluate the growth of the RasV12 tissues depleted for 
different DNA repair proteins as a measure of the dependency of those tissues to the 
specific DNA repair pathways.  
In most of the cases, we did not observe a significant difference in the growth 
capacity of the RasV12 tissue. However, for some genes we did find an increased 
growth, suggesting that, contrary to what we thought, different DNA repair pathways 
are slowing down tissue growth. Maybe these DNA repair pathways act by 
preventing the acquisition of new mutations that allow RasV12 cells to overcome their 
G2 arrest.  Only in one case did we find a significant reduction in tissue growth, 
discouragingly another gene in the same pathway showed the opposite effect (Fig 
10A). 
Then, we evaluated the effects on tissue growth at the level of pathways instead of 
at the level of individual genes as before, to see if we could find any statistically 
significant trend.  We found that the depletion of the FA, NER and NHEJ gave rise to 
an increase in tumor growth (Fig 10B), suggesting that, in general, the presence and 
activity of the different DNA repair pathways contribute to the stability of the tumor 
genome, thus imposing a break on tumor growth. The only exception was the 
mismatched repair pathway which shows a small although significant decrease in 
tissue size. The depletion of Homologous recombination or BER did not produce any 
effect. The lack of response to the depletion of homologous recombination genes, 
which should be the main repair pathway given the fact that most of the RasV12 cells 
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are in G2 phase, may be a consequence of the lack of ATR activity and consequent 
lack of HR repair.   
 
 
Figure 10. Interaction between RasV12 and different DNA damage repair pathways. 
(A) Graphs representing the growth of wing discs expressing RasV12 together with RNA-i 
for genes involved in different DNA repair pathways under the control of the hh-gal4 
driver. The growth is expressed as the posterior to anterior size ratio. (B) Summary of the 
results grouped by repair pathway. 
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3. RasV12 and cell death. 
The promotion of survival is one of the main downstream functions of Ras proteins. In 
Drosophila eye discs it has been shown that RasV12 can block apoptosis at the level 
of pro-apoptotic protein Hid through MAP kinase signaling (Bergmann et al., 1998; 
Kurada & White, 1998). Given the amount of DNA damage present on RasV12 
tissues, we decided to investigate whether apoptosis was being induced in such 
tissues and whether Ras expression had an antiapoptotic role in our system.  
3.1 RasV12 blocks cell death downstream of p53. 
First, we monitored cell death upon cell cycle induction by overexpressing E2F, CycE, 
and RasV12 or depleting Rbf.  
 
 
Figure 11.  Cell cycle and IR induced apoptosis blocked in RasV12 discs. Wing 
imaginal discs expressing the indicated transgenes under the control of the ap-gal4 (A) 
or hh-gal4 driver (B, B’). Discs were stained for DAPI in blue (A-B’) TUNEL in green (A) Ci 
in green (B,B’) and Dcp1 in red and white (B,B’). Discs in B’ were subjected to a 40Gy 
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dose of irradiation and dissected 5h after.  (A-B’) White lines indicate he are of transgene 
expression.  
 
In all cases, except for RasV12 expressing cells, there was a significant induction of 
apoptosis as seen by TUNEL assay (Fig 11A), suggesting that RasV12 is indeed 
capable of blocking apoptosis induced by an accelerated G1/S transition. In order 
to see if this was a general response, we analyzed cell death by staining for the 
effector caspase Dcp-1 after irradiation of RasV12 tissues (Fig 11B-B’). Again, RasV12 
is capable of completely blocking IR induced apoptosis.  
 
Figure 12. p53 activation in RasV12 discs.  Third wing imaginal discs expressing the 
indicated transgenes under the control of the hh-gal4 driver for 3 days (A-B’) or 16 hours 
(C). Discs were stained for Ci in red (A-B’) and in green (C), for DAPI in blue (A-B’) and 
dcp1 in red (C). Discs in A-B’ were labelled in green with the expression of a p53 activity 
sensor based on the 5’hid regulatory region fused to GFP. Discs in A’ and B’ were 
subjected to 40Gy irradiation and dissected 5 hours after.  
 
At this point, we wondered whether Dp53 was being activated by RasV12 expression. 
In order to test that, we used a Dp53 activity reporter that consists of the 5’ region of 
the hid gene (Tanaka-Matakatsu et al., 2009) that responds to Dp53 (Fig 12 B-B’). 
Although the levels were not very high, we observed increased expression of the 
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Dp53 reporter upon RasV12 expression (Fig 12 A).  Furthermore, when we irradiated 
these discs, there was a consistent upregulation of the reporter throughout the tissue, 
with the levels being higher in RasV12 cells (Fig 12 A’). Finally, we showed that RasV12 
cells reduce cell death induced by Dp53 overexpression (Fig 12 C), indicating that 
RasV12 is blocking cell death downstream of Dp53.  
3.2 ERK depletion in RasV12 tissues promotes cell death.  
One of the main functions downstream of Ras is to promote cell survival. In the 
developing eye of Drosophila, it has been previously shown that RasV12 has an 
antiapoptotic role in preventing Eiger or Reaper induced cell death and that this 
antiapoptotic role depends on MAPK/ ERK signaling.  Therefore, we wondered 
whether RasV12 was also blocking DNA damage-induced cell death through ERK 
signaling.  
Figure 13. ERK prevents p53 induced cell death. (A-B) Wing imaginal discs expressing 
the indicated transgenes under the control of the hh-gal4 driver. (A’, B’) Magnification of 
the imaginal discs depicted in A and B respectively. Discs were irradiated with a 40Gy 
dosage, dissected 5 hours after and stained for DAPI (blue), Ci (green) and Dcp1 (red 
and white).  
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In order to test that, we depleted ERK in RasV12 expressing cells and irradiated them 
with a 40Gy dose to induce DNA damage. Unlike RasV12 cells, RasV12 cells 
depleted for ERK are extremely sensitive to irradiation-induced DNA damage and 
massively die by apoptosis (Fig 13 A-A’). Moreover, this IR-induced cell death is 
dependent on p53 activity, since co-depletion of ERK and p53 eliminates cell death 
in RasV12 discs (Fig 13 B-B’).  
3.3 RasV12 blocks apoptosis by transcriptional and post-
transcriptional mechanisms. 
Previous contrasting reports suggest that the RasV12-induced blockage of apoptosis 
can be achieved by either transcriptional regulation of the gene hid or by the ERK-
mediated phosphorylation of hid protein (Bergmann et al., 1998; Kurada & White, 
1998).  
In order to elucidate if either of these two mechanisms applies in our case, we first 
depleted the Ets transcription factor Pointed which acts downstream of ERK. Upon 
depletion of pointed alone or in combination with RasV12 expression, we did not 
detect any increase in cell death (Fig 14 A). However, when we irradiated those discs 
we observed an increase in Dcp1 labelled cells specially in RasV12 tissues when 
compared to pointed-i irradiated cells (Fig 14 A’) but not as high as in RasV12 ERK 
depleted cells (Fig 13 A). These results suggest that ERK can act through activation of 
pointed in order to regulate gene expression and promote survival of the cells. 
Whether this effect is mediated by hid or not remains to be explored.  
To test the possible posttranscriptional regulation of apoptosis by ERK, we depleted 
KSR, a scaffolding protein that is responsible for sustaining ERK cytoplasmic activity 
(Casar, Pinto, & Crespo, 2008). Upon KSR depletion we did not observe any increase 
in cell death (Fig 14 B). However, upon irradiation, there was an increase in the 
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amount of dcp1 labelled cells both in wild type and RasV12 expressing cells (Fig 14 
B’). These results indicate that ERK cytoplasmic activity plays a role in 
posttranscriptional modifications that inhibit apoptosis and promote survival. Again, 
we have not explored whether this effect is mediated by hid or not.  
 
 
Figure 14. Mechanisms of ERK dependent apoptosis inhibition. (A-B’) Third instar wing 
imaginal discs expressing the indicated transgenes under the control of the hh-gal4 driver. 
Discs in A’ and B’ were subjected to a 40Gy irradiation and dissected 5 hours after. All 
wing discs were stained for DAPI (blue), Ci (green) and Dcp1 (red and white).  
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Together, both results indicate that upon RasV12 expression and ERK activation 
apoptosis can be blocked by different means involving both transcriptional and 
posttranscriptional changes. 
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4. Homeostatic effects of ERK signaling in response to 
irradiation. 
We observed that RasV12 tissues promote survival to irradiation via the activation of 
ERK signaling. We wondered whether this mechanism was also acting in wild type 
tissues to promote survival of irradiated cells and to maintain tissue homeostasis.  
4.1 ERK activation in response to irradiation.  
First, we wondered if ERK was activated upon irradiation. To test that, we subjected 
wild type discs to irradiation and measured the mean intensity of pERK, the active 
form of ERK. 
 
Figure 15. IR induced ERK activation.  (A,B,C-D)Third instar wing discs stained for pERK 
(A,D, white), Capicua (B, white), DAPI (C-D, blue) and Ci (D, green). (C) Discs carry the 
mini-cic reporter of ERK activity which gets delocalized from the nucleus upon ERK 
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activation. Discs in A,B,C (right panel) and D were irradiated with a 40Gy dose. (A’, B’) 
quantification of the mean intensity levels of pERK (A’) and Cic (B’) throughout the disc.  
 
We observed a significant increase in pERK mean intensity upon irradiation 
compared to non-irradiated discs (Fig 15 A-A’). We also measured the mean intensity 
of Capicua, a transcriptional repressor that is targeted for degradation upon ERK 
activation. Consistent with an ERK activation, the levels of Capicua were significantly 
decreased upon irradiation (Fig 15 B-B’). We used a mini-cic reporter that gets 
delocalized from the nucleus upon ERK activation (Moreno et al., 2019) to further 
confirm ERK activation upon irradiation (Fig 15 C-C’). Then we decided to test if the 
irradiation induced ERK activation is dependent on the activity of the DNA damage 
response. We depleted ATM and  
ATR in the posterior compartment of the discs and then irradiated them; we used the 
anterior compartment as an internal wild type control. In doing so, we did not find 
any difference in pERK levels between anterior and posterior compartments of 
depleted discs and neither with mock GFP depleted discs (Fig 15 D) indicating that 
ERK activation is independent of the DDR.  
On the other hand, we tested whether ERK activation had any role in the DNA 
damage response. We did not find any difference in H2Av phosphorylation between 
wild type and ERK depleted cells upon irradiation (Fig 16 A). Similarly, we could not 
detect any difference in the induction of G2 arrest (Fig 16 B, C), indicating that 
endogenous ERK levels do not play a role in the activation of the DDR upon 
irradiation.  
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Figure 16. Role of ERK on the DNA damage response. (A, B) Third instar wing imaginal 
discs expressing the indicated transgenes under the control of the hh-gal4 driver. Discs in 
A (left panels) and B were irradiated at 40 Gy and dissected 2 or 5 hours after irradiation. 
(A) discs stained for pH2Av in magenta and white. (B) Discs stained for pH3 in red, Ci in 
green and DAPI in blue. (C) Scatter plot showing the mitotic pH3 positive cells per area. 
Individual values, mean and standard deviation are represented 
 
 
Once we saw that ERK is activated by irradiation, we checked whether ERK depletion 
would promote cell death with and without irradiation. In both cases, there was 
increased apoptosis. However, the number of apoptotic cells marked by Dcp1 
staining was much higher upon irradiation treatment (Fig 17 A-B). Furthermore, cell 
death could be rescued by Dp53 depletion (Fig 17 C) or the expression of a 
microRNA that targets the three Drosophila proapoptotic genes hid, reaper and grim 
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(Fig 17 D). Moreover, we found that p53 activity was not affected by ERK depletion 
suggesting that ERK is acting downstream of p53 (Fig 17 E).  
 
 
Figure 17. ERK antiapoptotic signaling. (A-D) Third instar wing imaginal discs expressing 
the indicated transgenes under the control of the hh-gal4 driver. Discs were stained for 
DAPI (Blue and white) and dcp1 (red and white). (E) Discs labelled with DAPI (blue), Gal4 
(red) and p53 activity sensor (green and white). (B-E) Discs were irradiated at 40Gy and 
dissected 5 h after.  
 
 
Given the homeostatic role of ERK in response to irradiation, we decided to check if 
ERK activation could have a role in a developmentally controlled setting. We used 
the elav-Gal4, Tub-Gal80ts driver in order to express the transgenes in the 
differentiated photoreceptor cells of the eye disc.  Upon ERK depletion, we found a 
quite strong reduction in the eye size, uncovering a pro-survival role of ERK during a 
developmentally regulated process. In order to quantitatively compare different 
phenotypes, we elaborated a phenotypic classification that allowed us to quantify 
the percentage of each phenotype according to their severity, ranging from strong 
to normal/ wild type like (Fig 18 A). As previously shown, Dp53 depletion and miRHG 
expression lead to a rescue of the eye ERK reduced size even back to normal 
proportions (Fig 18 B). However, we never get a 100% rescue reflecting the role of 
MAPK-ERK signaling in photoreceptor development. 
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Figure 18. Endogenous role of ERK in preventing apoptosis. (A) Adult eyes of male flies 
expressing the indicated transgenes under the control of the elav-gal4 driver. Each fly is 
a representative image of the phenotypic divisions that we made in order to quantify the 
degree of the effect. (B) Quantification of the % of each eye phenotype in the given 
genotype with the following n: erk-i (n=60) , erk-i, p53-i (n=312), erk-I, miRHG (n=136).  
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5. Selective killing of RasV12 cells. 
Given its unique nature, Ras is known as the undruggable oncogene. Most common 
oncogenic Ras mutations actually interfere with its enzymatic activity, inhibiting its 
capacity to hydrolyze GTP, thus rendering them in a constitutively active state 
(Pylayeva-Gupta et al., 2011). Directly blocking Ras has proven very challenging, 
therefore many of the strategies to block Ras have been to directed to target the 
downstream signaling pathways such as MAPK and PI3K.  Unfortunately, many of 
these have failed due to the capacity of these cells to bypass this blockade and 
become resistant to therapy. Another strategy has been to try to exploit tumor cell 
dependencies in order to find synthetic lethal interactions that can specifically affect 
and kill tumor cells rather than wild type ones. On that note, we wondered whether 
we could take advantage of the intrinsic replicative stress and DNA damage found 
in RasV12 cells and their dependency on ERK signaling to survive, in order to 
selectively kill these cells. 
5.1 Genetic ERK inhibition. 
Our first strategy consisted of the combination of genetic ERK depletion together with 
ionizing irradiation. Given the fact that ERK has a homeostatic role in radioresistance 
of wild type cells as well, we had to establish a selective range of irradiation. To do 
that, we decided to test different doses of irradiation in order to find one that would 
synergize with the endogenous to RasV12-induced DNA damage but would not affect 
the wild type cells.  
We found that upon ERK depletion, RasV12 cells were sensitized to all the different 
doses of irradiation (Fig 19 A, quantification in B, blue lines).  However, only at 
intermediate (16Gy) and high (24Gy) levels of irradiation RasV12 cells showed higher 
levels of apoptosis than wild type ERK depleted cells (Fig 19 A, quantification in B, 
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red lines). These results suggest that there might be a therapeutic opportunity for the 
combination of ERK depletion and irradiation to treat Ras activated tumors.  
 
Figure 19. Radiosensitivty of ERK depleted RasV12 cells. (A) Wing imaginal discs 
expressing the indicated transgenes under the control of the hh-gal4 driver and subjected 
to different doses of irradiation. Discs were stained for DAPI (blue), Ci (green) and Dcp1 
(red and white). (B) Scatter plot showing the quantification of the percentage of posterior 
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area that is covered by Dcp1 of the discs in A. Average, SD and individual wig disc 
measurements are shown.  Statistically significant differences based on Student’s t-test 
are indicated in black and red. Comparisons of differences (in blue) were performed to 
quantify the differences in the radiosensitivity of RasV12 vs wild type tissues upon ERK 
depletion.  
 
We propose that the sensitivity of ERK depleted RasV12 cells to irradiation is due to 
the high levels of DNA damage that they carry as a consequence of their aberrant 
cell cycle progression. Both MAPK and Pi3K signaling pathways have been shown 
to promote cell proliferation via induction of G1/S transition (David A Prober & Edgar, 
2002). After ERK depletion the MAPK pathway would be shut down leaving Pi3K 
signaling to promote proliferation. We wondered whether Pi3K signaling was 
necessary for the sensitivity of RasV12 cells to ERK depletion. Indeed, when we co-
depleted ERK and Pi3K at the same time, there was a significant rescue of the cell 
death induced after a 16 Gy dose of irradiation (Fig 20 A-B).  
 
Figure 20. PI3K in RasV12 radiosensitivity. (A) Wing imaginal discs expressing the 
indicated transgenes under the control of the hh-gal4 driver,  stained for DApI (blue), Ci 
(green) and Dcp1 (red and white) and dissected 5 hours after a 16 Gy irradiation dosage.  
(B) Scatter plot quantifying the percentage of posterior area that is covered by Dcp1; 
Mean, SD and individual values are represented. Student’s t-test was used to test for 
statistical significance. 
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As a control, we checked that both ERK and AKT phosphorylation are actually 
increased upon RasV12 expression (Fig 21 C, C’).  The ERK RNAi used to deplete 
ERK was capable of reducing pERK staining both in wild type and RasV12 cells when 
compared to control discs (Fig 21 A, B, D) but not pAKT (Fig 21 A’, B’, D’). In discs 
expressing ERK-i and a dominant negative form of PI3K there was a decrease in 
both pERK and pAKT.  
 
Figure 21. ERK-i and PI3K-DN deplete ERK and PI3K levels. (A-E’) Wing imaginal discs 
expressing the indicated transgenes under the control of the hh-gal4 driver. Discs were 
stained for DAPI in blue and (A-E’), Ci in green (A-E’), pERK in red and white (A-E) and 
pAKT in red and white (A’-E’).  White lines indicate the area of transgene expression.  
 
 
Given the success in radiosensitizing RasV12 cells by genetic ERK depletion, we 
decided to try this same strategy against a more aggressive RasV12 driven tumor 
model. In order to do that, we took advantage of the already established and well-
known RasV12, Scribble model. These tumors rely on the overexpression of RasV12 
together with the depletion of the polarity determinant Scribble, producing highly 
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proliferative tissues presenting malignant characteristics such as developmental 
delay and invasive capacity (Brumby & Richardson, 2003; Pagliarini & Xu, 2003).  
Excitingly, we were capable of inducing apoptosis of the RasV12, scrib-i cells by 
genetically depleting ERK in combination with different doses of ionizing radiation 
(Fig 22 A, quantification in B, comparison in black). However, the extent of this 
apoptosis is always lower than in wild type ERK depleted cells (Fig 22 B, comparison 
in red) making RasV12, scrib-i cells less radiosensitive than wild type (Fig 22 B, 
comparison in blue).  
 
Figure 22. Genetic ERK depletion in Ras,scrib-i neoplasic tumors. (A) Third instar wing 
imaginal discs expressing the indicated transgenes under the control of the hh-gal4 driver, 
control (left panels) and ERK depleted (right panels). (B) Scatter plot showing the 
quantification of the percentage of posterior area that is covered by Dcp1 of the discs in 
A. Average, SD and individual wig disc measurements are shown.  Statistically significant 
differences based on Student’s t-test are indicated in black and red. Comparisons of 
differences (in blue) were performed to quantify the differences in the radiosensitivity of 
RasV12, scrib-i vs wild type tissues upon RNAi mediated ERK depletion. 
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This lack of specific radiosensitivity could be explained in different ways. On the one 
hand, it is possible that emerging properties of RasV12, scrib-i tumors make them 
more resistant to cell death than RasV12 tumors. On the other hand, it could be a 
consequence of the timing of transgene expression. We induce the tumor and 
deplete ERK at the same time without giving time for the tumors to form (Fig 22 C).  
In order to avoid this second possibility, we decided to move to a chemical method 
of ERK inhibition, that allows us to uncouple tumor formation and ERK depletion.  
5.2 Chemical ERK inhibition. 
Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 proteins. It 
prevents RAF-mediated MEK phosphorylation and activation, thus blocking ERK 
activation (Gilmartin et al., 2011; Sakai et al., 2011).  We chose Trametinib as ERK 
inhibitor because it is an already FDA approved drug for the treatment of metastatic 
melanoma (Flaherty et al., 2012) and is currently under clinical trial for its use in other 
types of cancer. 
 
Figure 23. Trametinib is efficient in inhibiting ERK activation both in wild type and 
RasV12, scrib-i discs. (A-B) third instar wing imaginal discs expressing the indicated 
transgenes under the control of the hh-gal4 driver. Discs were treated with either DMSO 
or trametinib at 2µM concentrations and stained for DAPI (blue), Ci (green) and pERK 
(red and white).  
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Although previous reports showed the efficacy of trametinib in inhibiting ERK 
phosphorylation and activation, via western blot, at similar concentrations as we use, 
the exposure time was much longer (Levine & Cagan, 2016; Song et al., 2019). 
Therefore, we decided to test the efficacy of trametinib in our model. When we 
subjected wild type and RasV12, scrib-i larvae to 2 days of Trametinib treatment, we 
observed a vast reduction in pERK levels detected by immunostaining (Fig 23 A, B).  
 
Figure 24. Chemical ERK depletion in Ras,scrib-i neoplasic tumors. (A) Third instar wing 
imaginal discs expressing the indicated transgenes under the control of the hh-gal4 driver, 
DMSO control (left panels) or trametinib treated (right panels). (B) Scatter plot showing 
the quantification of the percentage of posterior area that is covered by Dcp1 of the discs 
in A. Average, SD and individual wig disc measurements are shown.  Statistically 
significant differences based on Student’s t-test are indicated in black and red. 
Comparisons of differences (in blue) were performed to quantify the differences in the 
radiosensitivity of RasV12, scrib-i vs wild type tissues upon chemical ERK depletion. 
 
We fed RasV12, scrib-i larvae with food containing either DMSO or Trametinib at a 
2µM concentration 1 day after the initiation of transgene expression (Fig 24 C). In 
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order to assess the interaction between Trametinib treatment and irradiation, larvae 
were exposed to different doses of ionizing radiation two days after the initiation of 
Trametinib treatment. Wing discs expressing RasV12, scrib-i and treated with 
Trametinib were more sensitive to low and intermediate doses of irradiation that wild 
type cells but not at high doses (Fig 24 A, B comparisons in red). 
 
Figure 25. p53 activity and DNA damage in RasV2,scrib-i wing imaginal discs. (A,B,D) 
Third instar wing imaginal discs expressing the indicated transgenes under the control of 
the hh-gal4 driver and stained for (A,B,D) DAPI in blue, Ci in red and (A,B) pH2AV in green 
and white. Discs in D are labelled in green and white by a p53 activity sensor. (C) Scatter 
plot shows comet assay quantification in terms of the tail moment (%Tail DNA x Tail 
Length) of over 200 cells per condition, GFP-i in gray and RasV12,scrib-i in green.  
 
Surprisingly, the sole action of Trametinib was also capable of inducing cell death in 
RasV12, scrib-i discs (Fig 24 A, B comparisons in black). It has been shown that these 
tumors activate proapoptotic Jun kinase signaling (Igaki et al., 2006). Furthermore, 
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these cells present high levels of DNA damage (Fig 25 C) but fail to induce H2Av 
phosphorylation (Fig 25 A-B). We also observed an increased p53 activity (Fig 25 D) 
when compared to RasV12 alone wing discs (Fig 12 A). Altogether these data point 
to the possibility that RasV12, scrib-i discs are under much higher apoptotic pressure, 
making them very sensitive to chemical inhibition of ERK signaling once the tumor 
has been formed.  
5.3 Targeting malignant Ras dependent tumors. 
Clonal induction of tumor growth is a more accurate representation of the tumorigenic 
process where most probably a single cell acquires a mutation that makes it highly 
proliferative leading to tumor initiation.  
In that regard, clonal expression of RasV12 together with scribble homozygous 
mutations has extensively been used to model different characteristics of tumor 
growth, such as the capacity of these tumors to invade neighboring tissues (Uhlirova 
& Bohmann, 2006b), the induction of systemic effects such as cachexia (Figueroa-
Clarevega & Bilder, 2015) or developmental delay of pupariation. We have taken 
advantage of this clonal model to evaluate, not only, the proapoptotic effects of 
Trametinib treatment, but also, its effects on tumor growth and at the whole larva 
level.   
In order to evaluate the effect of Trametinib in tumor growth, 4 days old early L3 
RasV12, scrib-/- larvae were fed with 2µM DMSO or Trametinib. Then, 2, 4, 6 or 8 days 
after Trametinib treatment initiation, larvae were removed from the food (Fig 26 A) 
and imaged to evaluate tumor burden (Fig 26 B). DMSO treated larvae showed a 
rapid increase in tumor burden over time while Trametinib treated larvae showed a 
very much reduced and more constant tumor burden.  
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Figure 26. Trametinib treatment for reducing tumor burden and developmental delay 
through specific induction of apoptosis. (A) Diagram showing the transgene induction 
time and the trametinib administration period at day 4 after egg laying. (B) Third instar 
larvae carrying eye GFP clones, either wild type or RasV12, Scribble mutant. Upper row 
larvae are mock treated with DMSO and lower row larvae are treated with 2uM 
Trametinib. Larvae were treated from day 4 onwards and collected at day 6, 8, 10 and 
12 after egg laying. Clones are shown in green. (C) Graph showing the progression of 
pupariation of larvae carrying wild type clones (gray) or RasV12, scrib-/- clones (green) 
and treated with DMSO (solid line) or 2uM Trametinib (dashed line). n (wild-type + 
DMSO)= 188; n (wild-type + TRA)= 293; n (RasV12 scrib + DMSO)= 217; n (RasV12 scrib + 
TRA)= 172. The percentages were calculated based on the total number of larvae. (D) 
Cephalic complexes (Brain, ventral nerve cord and eye-antenna discs) of larvae carrying 
either wild type or RasV12, scrib-/- GFP expressing clones. Treated with DMSO (upper 
panel) or Trametinib 2uM (lower panel) at day 4 ael and dissected at day 6,8,10 and 12 
ael. Cephalic complexes are labelled by GFP (green) and stained for DAPI (blue) and 
Elav (red). (E) Eye-antenna imaginal discs with GFP labelled (green) RasV12, Scrib-/- clones 
treated with DMSO or Trametinib 2uM and stained for DAPI (blue) and Dcp1 (red). (F) 
Scatter plot showing the percentage of GFP area over the total area of the discs in E. 
Individual values, mean and standard deviation are shown. Student’s T-test was used to 
compare the two populations with a p>0.0001.  
 
Regarding developmental timing, RasV12,scrib-/- larvae stay in the food as larvae 
way past the normal pupariation time, around day 6 after egg laying (Fig 26 C solid 
grey line).  Indeed, very few pupae are formed and most larvae eventually die without 
entering into pupariation (Fig 26 C solid green line). However, after Trametinib 
treatment there is a significant rescue of RasV12,scrib-/- larvae pupariation (Fig 26 C 
dashed green line), with 50% of the pupas being formed at day 8, very much alike 
wild type Trametinib treated larvae (Fig 26C dashed grey line).   
Then we evaluated the effects of trametinib treatment on tumor growth, invasion and 
organization of cephalic complexes. While DMSO treated eye imaginal discs 
showed an exponential increase in clone growth, Trametinib treated eye discs 
showed a much slower increase in clonal area (Fig 26 D, upper panel). Furthermore, 
at late stages, DMSO tumors grew over the ventral nerve cord and completely 
disorganized brain structure, both effects were mostly rescued by Trametinib 
treatment (Fig 26 D, lower panel). Meanwhile, Trametinib treatment did not have any 
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major impact on the growth of wild type eye-antenna discs, although there was a 
defect in the differentiation of photoreceptor cells labelled with elav, consistent with 
the role of MAPK signaling in that process (Fig 26 D white arrows).  
Taking a closer look at day 6 eye discs, we observe a significant decrease in the 
clone area (measured as the percentage of the disc that is covered by GFP) (Fig 26 
E, F). In many cases, these clones colocalize with Dcp1 staining (Fig 26 E). 
 
 
Figure 27. Effects on tumor burden of short trametinib treatment. (A) Diagram showing 
the time of transgene induction and the trametinib administration period at day 5 after 
egg laying. (B) Eye-antenna imaginal discs with GFP labelled (green) RasV12, Scrib-/- 
clones treated with DMSO or Trametinib 2uM and stained for DAPI (blue) and Dcp1 (red).  
Scatter plot showing the percentage of GFP area over the total area of the discs. 
Individual values, mean and standard deviation are shown. Student’s T-test was used to 
compare the two populations with a p>0.0001. (C) GFP labelled RasV12, Scrib-/- clones of 
6 days larvae treated with DMSO or trametinib (2uM) for 1 day. Stained for DAPI (blue) 
and Dcp1 (red). (C’) Magnifications of the clones shown in C.  
 
 
Pulsatile trametinib treatment has previously been shown to be useful for cancer 
treatment (Choi et al., 2019), therefore we tested the effect of a short, 1 day, 
Trametinib treatment (Fig 27 A). In these conditions, we also observed a significant 
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decrease in clone area, although less pronounced than with longer exposures (Fig 
27 B). Again, most of the clones colocalized with Dcp1 staining and showed 
apoptosis marks such as the presence of pyknotic nuclei (Fig 27 C, C’). 
These results indicate that the effect of Trametinib on RasV12, scrib mutant cells is 
mainly to promote apoptosis of these cells rather than preventing their growth.  
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6. Transcriptional response of RasV12 cells. 
We evaluated the transcriptional response induced by RasV12 expression in wing 
imaginal discs. To do that, we expressed RasV12 under the control of the ap-gal4 
driver for 3 days, we dissected the discs and FACS sorted RasV12 cells according to 
myristolated Tomato levels. We extracted mRNA and performed a QUANT-seq 
analysis. This technique allows the measurement of the expression levels of each 
mRNA and is based on the use of oligo dT primers for mRNA amplification and 
sequencing. IRB Barcelona bioinformatics facility analyzed the data, and we 
obtained a list of up and downregulated genes. Then, they performed a gene set 
enrichment analysis based on the gene ontology biological processes lists (GOBP).  
Table 2. Gene set enrichment analysis of RasV12 expressing cells. Representative up 
and downregulated gene sets in RasV12 cells compared to wild type cells. All data can 
be found under the following ID: GSE127228 at the Gene Expression omnibus web page.  
 
  
 
 
Among the upregulated gene sets we find several RTK signaling dependent 
processes (Table 1, for full GOBP see supplementary table 1) which makes us 
confident that the detected genes and gene sets are actually a consequence of 
RasV12 expression. Among the downregulated gene sets we find very interesting 
ontologies. Consistent with the low EdU incorporation and the G2 arrest present in 
RasV12 cells, we find DNA replication is downregulated, we can also find gene sets 
related to DNA and cell cycle regulation (Table 1, for full GOBP see supplementary 
DEREGULATED GENE SETS SIZE NES FDR q-val
Epidermal growth factor receptor signaling pathways 58 1,868 0,189
Photoreceptor cell development 92 1,624 0,218
Sensory organ development 419 1,619 0,218
DNA replication 80 -2,132 0,009
Chromatin assembly or disassembly 32 -1,866 0,056
DNA damage checkpoint 71 -1,768 0,087
Regulation of cell cycle process 173 -1,649 0,109
UP
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table 2). Interestingly, also gene sets related to DNA damage checkpoints are 
downregulated. Although many of the genes are not significantly downregulated, 
when evaluated as a whole there is a solid tendency (supplementary table 3 and 4).  
Several micro RNAs have been shown to target different DNA damage related 
genes, specifically ATM and ATR (He et al., 2016). Since we were interested in the 
regulation of the DNA damage response by RasV12, and given the fact that we do 
not find any specific genes downregulated that could explain the inhibition of H2Av 
phosphorylation, we decided to perform a microarray to evaluate the expression of 
the different microRNAs present in Drosophila.  
Table 3. List of up and downregulated microRNAs in cells expressing RasV12. Up and 
downregulated microRNAs upon RasV12 expression based on microarray analysis. 
 
 
We found a total of 12 miRNAs that were upregulated (Table 2). We used target 
scan fly (Agarwal et al., 2018) to look for predicted miRNAs targeting our proteins of 
miRNA FOLD CHANGE P.Value
dme-miR-10-3p 8,426 0,017
dme-miR-263b-5p 5,702 0,020
dme-miR-34-3p 5,129 0,020
dme-miR-92a-5p 5,049 0,023
dme-miR-277-3p 4,682 0,095
dme-miR-34-5p 3,512 0,018
dme-miR-2a-3p 2,786 0,218
dme-miR-7-5p 2,698 0,290
dme-miR-998-3p 2,411 0,238
dme-miR-9a-5p 2,372 0,548
dme-miR-92b-3p 2,322 0,184
dme-miR-317-3p 2,190 0,213
dme-miR-306-5p -2,001 0,339
dme-miR-4970-5p -2,080 0,079
dme-miR-285-3p -2,581 0,548
dme-let-7-5p -2,656 0,519
dme-miR-989-3p -4,150 0,015
dme-miR-989-5p -4,179 0,073
U
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interest ATM and ATR. Then we crossed the list of putative miRNAs offered by target 
scan fly with the results of our microarray. We found no upregulated microRNA that 
was predicted to target ATM, however, we did find mir-277-3p as a putative ATR 
binding microRNA.  
Based on the identification of ATR as a putative target of mir-277-3p, we decided to 
express the sponge for this miRNA in RasV12 expressing discs. When we checked 
H2Av phosphorylation as a read out of ATR activity, we were disappointed to find 
that mir-277 sponge had no effect in RasV12 expressing discs (Fig 28A), suggesting 
that the inhibition of ATR function is not dependent on this micro RNA.  
 
 
Figure 28. mir-277 sponge expression in RasV12 discs. Third instar wing imaginal discs 
expressing the indicated transgenes under the control of the hh-gal4 driver. Discs were 
stained for DAPI (blue), ci (red) and pH2Av (green and white).  
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7. Non-autonomous effects induced by RasV12 expression. 
In the last few years, Drosophila has been used to assess the interactions between 
different tumor populations,  as well as the relationship between the tumor and the 
surrounding wild type cells that conform the tumor microenvironment (Herranz, Weng, 
& Cohen, 2014; Katheder et al., 2017; Muzzopappa et al., 2017). This is due to the 
plethora of genetic tools that allow us to induce gene expression in specific organs 
and tissues and evaluate the effect of this expression in surrounding tissues. 
7.1 Non-autonomous cell death and DNA damage.  
During the course of our experiments to evaluate the role of RasV12 in DNA damage 
response and apoptosis, we realized that while there was no autonomous effect (Fig 
29 A-D), there was an increase in pH2AV (Fig 29 A-B green line) and in apoptosis 
(Fig 29 C-D green line) in the neighboring anterior compartment.  
 
Figure 29. Non-autonomous DNA damage and apoptosis after RasV12 expression. (A-
D) Third instar wing imaginal discs expressing the indicated transgenes in the posterior 
compartment under the control of the en-gal4 driver. Discs were stained for DAPI (blue), 
Ci (green) marking the anterior compartment and ph2Av (A,B) and TUNEL (C,D) in red 
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and white. Green dashed lines outline the area of the anterior non-autonomous 
compartment. 
 
Furthermore, this non-autonomous phenotype was only found in RasV12 expressing 
discs but not when we induced G1/S transition by other means as CycE and E2F 
overexpression or Rbf downregulation (Fig 30 A-D green area), suggesting that this 
non-autonomous effect is Rasv12 specific. However, it is also possible that the lack of 
non-autonomous phenotype in these cases is due to the fact that a big amount of 
this cells die (Fig 11 A) and the discs do not overgrow or induce any type of tumor 
formation.  
 
Figure 30. RasV12 induced non-autonomous DNA damage is not recapitulated by 
induction of G1/S transition. (A-D) Third instar wing imaginal discs expressing the 
indicated transgenes under the control of the en-gal4 driver. Discs were stained for DAPI 
(blue), Ci (green) and pH2Av (red and white).  Non-autonomous compartment is marked 
with dashed green lines.  
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7.2 Non-autonomous DNA damage and nucleoside competition. 
We have shown that RasV12 cells present replicative stress and replication defects. 
Furthermore, we have seen in our RNA-seq that the Ribonucleotide reductase, the 
enzyme responsible for the late steps of deoxynucleotide biosynthesis, is 
downregulated.  
 
Figure 31. RasV12 induced non-autonomous effects and nucleoside transporters. (A-B) 
third instar wing imaginal discs expressing the indicated transgenes under the control of 
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the hh-gal4 driver. (A, B) Discs were stained for Ci in green, DAPI in blue and pH2Av in 
red and white. Dashed green lines outline the non-autonomous area. (A’, B’) Bar graph 
representing the amount of pH2Av positive cells per anterior area. Mean value and 
standard deviation are shown.  
 
There are two pathways for nucleotide synthesis: the de novo pathway involving the 
ribonucleotide reductase and the salvage pathway that aims to recycle bases and 
nucleosides for nucleotide synthesis. 
Given that the de novo pathway is hindered by the lack of ribonucleotide reductase, 
we hypothesize that RasV12 cells may strongly depend on the salvage pathways 
and compete with the cells in the anterior compartment for the uptake of nucleosides. 
This lack of nucleosides in the anterior compartment could lead to replication stress, 
DNA damage and apoptosis. In order to test this possibility, we decided to deplete 
the different nucleoside transporters present in Drosophila and evaluate the effect on 
non-autonomous DNA damage. Unfortunately, we did not observe any significant 
change in pH2Av upon depletion of the different transporters neither in wild type 
discs (Fig 31 A, A’) nor in RasV12 expressing discs (Fig 31 B, B’). We only depleted 
the transporters individually, and it is thus possible that the rest of them can 
compensate for the loss of one transporter.  
7.3 Non-autonomous effects and ROS.  
Another possibility to explain the presence of a non-autonomous effect relays on the 
presence of a secreted molecule that, even though is expressed by RasV12 cells, 
can reach the anterior wild type cells. We turned to the RNA-seq in order to look for 
upregulated secreted molecules that could be related to the non-autonomous role of 
RasV12.  The first upregulated gene that came to our attention was the Glutation S 
transferase D3 (GstD3). This gene is upregulated in response to ROS via the activity 
of the Nrf2 transcription factor. (Sykiotis, & Bohmann , 2008). We hypothesized that 
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ROS signaling could induce the oxidation of the DNA, thus causing DNA damage 
and cell death. In order to confirm the results of the RNA-seq, we used a GstD reporter 
to evaluate its expression in RasV12 wing discs. We observe high levels of GstD-GFP 
in the posterior autonomous compartment but also at the anterior-posterior boundary 
between compartments (Fig 32 A). Then we decided to overexpress different 
antioxidant enzymes in order to reduce the levels of ROS. When we overexpressed 
catalase or superoxide dismutase in combination with RasV12, we did not observe 
any reduction in the non-autonomous levels of either pH2Av (Fig 32 B, C) or cell death, 
(Fig 32 D, E) when compared to RasV12 alone (Fig 28 A-D).  
 
Figure 32. ROS present in RasV12 tumors and non-autonomous effects. (A-E) third instar 
wing imaginal discs expressing the indicated transgenes under the control of the en-gal4 
driver. Discs were labelled with gstD-GFP in red and white (A) and stained for DAPI in 
blue (A-E), Ci in green (A-E), pH2AV in red and white (B,C) and TUNEL in red and white 
(D,E). Autonomous compartment is marked by dashed green lines.  
 
7.3 Role of stat signaling in non-autonomous DNA damage and 
apoptosis. 
RasV12 has been shown to induce non-autonomous autophagy, as a way to provide 
building blocks for cellular growth, thus promoting tumor growth both in mammals 
and Drosophila (Guo et al., 2016; Katheder et al., 2017). Furthermore, increasing 
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evidence shows that autophagy may play a role in the regulation of DNA damage 
and apoptosis (Hewitt & Korolchuk, 2017). We wondered whether autophagy 
induction could be the cause of the non-autonomous DNA damage and apoptosis.  
 
Figure 33. RasV12 induced non-autonomous autophagy. (A-D) Third instar wing imaginal 
discs expressing the indicated transgenes under the control of the hh-gal4 driver. Discs 
were stained for DAPI in blue (A-C), Ci in green (A) and red (B,C),  mCherry-ATG8 in red 
and white (C-D), Upd-LacZ in green and white (A) and STAT92E-GFP in green and white 
(B). (C-D) magnifications of representative areas of the anterior and posterior 
compartments. 
 
It has also been shown that JAK/STAT signaling may play a role in the induction of 
non-autonomous autophagy (Katheder et al., 2017). Since Upd3 and Upd2 (JAK/STAT 
ligands) were upregulated in our RNA-seq, we decided to confirm those results. 
Although we could not detect high levels of Upd expression by using an Upd3-LacZ 
reporter (Fig 33 A), we could detect extended STAT activity (Fig 33 B) according to 
the STAT92E-GFP reporter.  Then, we checked for non-autonomous autophagy, by 
using a mCherry-ATG8 fusion protein, which can be found coating the autophagic 
vesicles. We observed induction of non-autonomous autophagy in RasV12 discs (Fig 
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33 D anterior) when compared to wild type discs (Fig 33 C anterior). We also 
observed an increase in autonomous autophagy although much lighter than the non-
autonomous (Fig 33 D posterior). 
 
Figure 34. Role of JAK/STAT in non-autonomous DNA damage and apoptosis. (A-C’) 
Third instar wing imaginal discs expressing the indicated transgenes under the control of 
the hh-gal4 driver. Discs were stained for DAPI in blue, Ci in red dcp1 in green and white 
(A-C) and pH2Av in green and white (A’-C’). Anterior compartment is outlined by dashed 
green lines.  (D) Scatter plot of the ratio of the posterior to anterior area, (E) Scatter plot 
of the amount of pH2Av positive cells relative to the anterior area. (D, E) single values, 
average and standard deviation are shown in both graphs. Controls in black and 
experiment in green.  
 
Then, we decided to analyze whether JAK/STAT signaling could have a role in the 
non-autonomous DNA damage and apoptosis. In order to do so, we expressed a 
dominant negative form of the receptor Domeless that acts not only by inhibiting the 
autonomous signaling but also by trapping the Upd ligands and preventing their 
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diffusion. In RasV12, domeDN discs, we observed a decrease in the amount of non-
autonomous DNA damage (Fig 34 B’,E) and cell death (Fig 34 B) as well as a 
reduction of the tumor growth (Fig 34 C). Furthermore, we overexpressed the ligand 
Upd in RasV12 discs and found a significant increase both in non-autonomous DNA 
damage (Fig 34 C’) and apoptosis (Fig 34 C), as well as an increase in tumor growth 
(Fig 34 D). Due to the experimental set up is impossible to say whether JAK/STAT 
signaling promotes a non-autonomous effect that then impinges on tumor growth or 
if, on the contrary, JAK/STAT autonomously promotes tumor growth which then 
increases the non-autonomous effects.  
 
Figure 35. JAK/STAT signaling and autophagy. Third instar wing imaginal discs 
expressing the indicated transgenes under the control of the hh-gal4 driver. Discs were 
stained for lysotracker (red and white), ci (green) and DAPI (blue). 
 
Seen that JAK/STAT signaling plays a role in, directly or indirectly, promoting non-
autonomous DNA damage and apoptosis, we wondered whether it could be doing 
so by inducing autophagy. In order to monitor autophagy, we used the lysotracker 
probe which is highly selective for acidic organelles and can be used to label 
lysosomes and autophagolysosomes. In RasV12 discs, we observed high lysotracker 
staining non-autonomously, similarly to Atg8. This signal is reduced by the expression 
of domeDN and increased by Upd overexpression both autonomously and non-
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autonomously (Fig 35). Altogether, these results suggest that RasV12 cells through 
unpaired and JAK/STAT signaling induce both autonomous and non-autonomous 
autophagy as well as tumor growth. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Discussion 
 
 
111 
1. RasV12 growth and cell cycle  
1.1. RasV12, G2 arrest and senescence. 
We and others have shown that the capacity of RasV12 overexpression, in wing 
imaginal discs, to promote tumorigenesis and growth is somehow limited. It has been 
proposed that RasV12 overexpression can lead to the acquisition of some 
senescence features (Nakamura et al., 2014) such as ß-Gal activity, H3K9 
trimethylation or increased cell size. However, these cells do not recapitulate a fully 
developed senescent phenotype. In this regard, the most interesting aspect to us is 
the tendency of these cells to arrest in the G2 phase of the cell cycle, which agrees 
with the presence of replication stress. It is curious that these cells are arrested in G2 
while their levels of the mitotic cyclin B are high, suggesting that something is 
imposing a brake on the progression of these cells through mitosis. We have shown 
that this arrest is independent of the DNA damage response pathway and of ATR 
and ATM activity. On the contrary, we found that the G2 arrest can be rescued by 
String overexpression. String (Cdc25) is the phosphatase responsible for the 
dephosphorylation of CDK1, and therefore, 
activation of mitotic CyclinB-CDK1 complexes 
that are necessary for G2/M transition. 
Activation of the DDR can lead to G2 arrest by 
phosphorylation and inhibition of String. 
However, in our case ,the inactivation of String 
seems to be independent of the DDR.  
Moreover, we found that string mRNA levels 
were downregulated in RasV12 expressing 
cells according to our Quant-seq results (Fig 
1). Although these results were never 
Figure 1. String expression in 
RasV12 vs wild type cells. Levels of 
string mRNA according to the three 
replicates of our Quant-seq.  
Adjusted p-value 1,62·e-12. 
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confirmed by qRT-PCR, and we did not check for the levels of phosphorylated String, 
we believe that in our case string is transcriptionally regulated by an unknown 
mechanism, rather than post-transcriptionally regulated by the DDR. 
String downregulation has been shown to play a role in the acquisition of resistance 
to ATR inhibitors in murine tumors (Ruiz et al., 2016). Thus, we wonder whether String 
depletion in RasV12 cells could be a mechanism to cope with the DNA damage and 
ATR inhibition that we observe in these cells. We wonder whether, when String is 
upregulated, these cells resume the cell cycle, prematurely enter into mitosis and 
accumulate more DNA damage. If that were the case, the prevention of G2 arrest 
could be used to increase the DNA damage present in RasV12 cells, and in 
combination with ERK depletion, to selectively target Ras cells. This may be 
accomplished by using Wee1 inhibitors. Wee1 is a CDK1 inhibitory kinase that is 
usually antagonized by the phosphatase activity of String. In the absence of String, 
Wee1 maintains CDK1 inhibited. By using Wee1 inhibitors, we could prevent the 
inhibition of CDK1 and therefore allow the resumption of cell cycle progression, which 
may lead to mitotic catastrophe in the presence of DNA damage. Wee1 inhibitors 
are currently undergoing clinical trials, and the combination of ATR and Wee1 
inhibitors has been shown to be synthetically lethal in breast cancer models (Bukhari 
et al., 2019).  
1.2. RasV12 and replication stress. 
In 1998 Karim and Rubin found that RasV12 expression led to an increase in EdU 
positive cells. However, we have observed the opposite, a reduction in the number 
of EdU positive cells upon RasV12 expression. But not only that, we have shown, 
through the use of an RPA reporter, that RasV12 expression in the wing imaginal disc 
leads to DNA replication stress. Furthermore, many of the RasV12 cells show aberrant 
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mitoses with DNA bridges, which are a feature of mitosis entry with an under-
replicated genome (Wise & Brinkley, 1997). These seemingly contradictory results 
may be explained by the differences in the induction protocol. They used a dpp-Gal4 
driver to constitutively drive RasV12 expression to the wing discs, and raised the flies 
at 25ºC leading to a rather mild expression of RasV12, where they even obtained 
viable adults.  In our case we used the hh-Gal4 driver to induce RasV12 expression 
in the whole posterior compartment of the wing disc, we used the Gal80ts repressor 
to prevent early transgene expression, and then, transferred the flies to 29ºC for 
maximal expression. It is possible that low levels of RasV12 expression lead to a 
proliferative phenotype without producing too much DNA damage and without 
eliciting a cell cycle arrest. We found that RasV12 expression drove a decrease in 
the amount of EdU positive cells but only after 3 days of expression. Although it is 
possible that we missed the first wave of Ras-induced proliferation, we could not 
observe an increase in EdU cells even examining the initial response after 15 hours 
of induction. We could try to test different induction times to capture this moment.  
Another element that suggested the presence of replicative stress is the 
downregulation of the gene ontology group of DNA replication. Among the genes 
downregulated in this group were the Ribonucleotide reductase, necessary for the 
production of nucleotides, and several MCM and Orc components, indispensable 
for origin licensing. However, whether this downregulation is a cause of the 
replication stress or a simple consequence of the overrepresentation of G2 arrested 
cells, we do not know.  
1.1. RasV12 and malignancy. 
The oncogene-induced DNA replication stress model proposed that, initially, 
oncogenic activation will lead to aberrant proliferation and activation of the DDR to 
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act as an antitumoral barrier (Halazonetis, Gorgoulis, & Bartek, 2008b). Our Ras 
model mimics a premalignant state where there is DNA damage and cells become 
arrested, in our case, independently of the DDR. Normally, RasV12 larvae pupariate 
with about one day delay with respect to wild type larvae. However, we believe that 
this is not enough time for RasV12 cells to overcome their senescence-like phenotype 
and to give rise to a malignant tumor. From time to time, we would get escapers that 
stayed longer in the food, even for two or three extra days. When dissected, the 
tumors were bigger, disorganized and presented MMP1 staining (Data not shown). 
This suggested that, if given enough time, RasV12 tumors would eventually overcome 
the cell cycle arrest and give rise to malignant tumors. It would be interesting to 
deeply evaluate the senescence and malignant status of these escaper larvae in 
order to prove our hypothesis. It would also be possible to implement a system in 
which we can induce the developmental delay of RasV12 larvae and analyze the 
tumor evolution in time.  
On the contrary, RasV12, scribble-i larvae have tumors with a high proliferation 
capacity, that are developmentally delayed, and show signs of malignancy as MMP1 
upregulation. How Scribble depletion induces the bypass of the G2 arrest, observed 
in RasV12 cells, to give rise to a malignant tumor is not completely clear. It has 
previously been shown that Scribble depletion in RasV12 expressing cells induces 
the delamination of some of the cells that activate JNK leading to a pro-tumorigenic 
transcriptional program (Uhlirova & Bohmann, 2006a). Previous work in Marco 
Milan’s group has shown that the Wingless and Unpaired molecules secreted from 
the delaminated cells are necessary for the growth and proliferation of the cells 
remaining in the epithelium (Muzzopappa et al., 2017). How these two molecules 
override the G2 arrest or if it is through a direct or indirect mechanism remains still to 
be explored. A full evaluation of the cell cycle status of the two tumor populations that 
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are formed in RasV12, scribble-i tumors would be interesting. Maybe understanding 
this mechanism would point towards a therapy to prevent the malignant 
transformation of RasV12 dependent adenomas.  
2. Ras V12 inhibition of the DDR 
2.1 ATR inhibition by Ras. 
Genetically, we have shown that RasV12 expression in the Drosophila wing imaginal 
disc leads to a decrease in H2Av phosphorylation in response to DNA damage and 
that this is due to the impairment of ATR function. How this ATR inhibition happens 
and whether it is transcriptional or post-transcriptional is still unresolved.  
With regard to the effectors of ATR regulation downstream of Ras, we do not know 
either. In order to find out, we could express RasV12 and block the downstream 
effectors of the different pathways and analyze the recovery in H2Av phosphorylation. 
However, it is possible that by blocking them we are eliminating the source of the 
damage itself. Therefore, negative results in these experiments would not exclude the 
involvement of these pathways in ATR regulation. Alternatively, mutations in Ras 
effector loop that specifically activate ERK, PI3K or Ral pathways were identified in 
mammals in 1995 (White et al., 1995). Given the conservation of this region of the 
Ras protein,  these mutant forms were also generated in flies in 1998 (F. D. Karim & 
Rubin, 1998). We could express these mutant forms and see if any of them 
recapitulates RasV12 effects in terms of ATR inhibition, at least in response to 
irradiation.  
2.1.1. Transcriptional regulation. 
The activation of the DNA damage response pathway is a rapid process that needs 
to happen immediately after the induction of the damage. Therefore, and although 
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ATR can be transcriptionally regulated by different proteins (Beesetti et al., 2017; Sethy 
et al., 2018), this does not seem to be the main regulatory element of ATR activity. 
We have not found an ATR downregulation in our transcriptomic analysis of RasV12 
cells. Furthermore, overexpression of ATR/mei41, which induces ATR activation (Bayer 
et al., 2018), does not result in an increase in H2Av phosphorylation in RasV12 (Fig 
2), suggesting that there is an alternative mechanism to prevent its activation. All in 
all, we do not think that ATR transcriptional regulation is playing a major role in our 
model.  
 
Figure 2. ATR overexpression in RasV12 cells. Third instar wing imaginal discs 
expression the indicated transgenes under the control of the hh-gal4 driver. Discs were 
stained with DAPI (blue), Ci (red) and pH2AV (green and white). Quantification of the 
number of pH2Av positive cells per area.  
 
2.1.2. Post-transcriptional regulation. 
Phosphorylation (activation) and dephosphorylation (inactivation) is the main way to 
rapidly regulate ATR activity in response to damage. In mammals, the most common 
way to check for the activation of ATR is to use phospho-specific antibodies which 
detect the phosphorylation of different residues on ATR and its target Chk1. However, 
in Drosophila we are lacking such antibodies, and, although there is conservation in 
ATR proteins, the mammalian antibodies have not been tested either. In order to 
confirm a possible posttranscriptional regulation of ATR downstream of RasV12, we 
could test the existing mammalian antibodies in the fly. Or even more interestingly, 
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we would like to evaluate if RasV12 causes ATR inhibition in mammalian cells. 
Disappointingly, although many reports link ATR regulation and Ras, they propose 
the opposite, that Ras, through ERK, promotes the activation of ATR signaling rather 
than its inactivation (Grabocka et al., 2014; Lee et al., 2017; Wei, Yan, & Tang, 2011).  
The Ras-induced ATR inactivation does not seem to depend on checkpoint 
phosphatases or microRNAs, and we do not have any putative target to be 
responsible for this regulation. In this context, a phospho-proteomic analysis of 
RasV12 expressing cells might help to define the phosphorylation status of ATR and 
its targets and also to identify possible mediators of this ATR inhibition.  
2.2 DDR inhibitors for cancer treatment.  
Studies in human cultured fibroblasts have shown that RasV12 overexpression 
induces DNA damage and oncogene-induced senescence, that is abolished by ATM 
depletion (Bartkova et al., 2006b; Di Micco et al., 2006). However similar experiments 
in mouse have shown that RasV12 overexpression leads to senescence in the 
absence of any DNA damage signaling (Efeyan et al., 2009). In this last report, they 
never actually looked into the DNA damage itself. Therefore, we do not know whether 
RasV12 expression in mouse induces DNA damage or not. In our model, we have 
found that RasV12 expression is capable of generating DNA damage while at the 
same time blocking the DNA damage signaling.  
It has been proposed that high levels of DNA damage response activation act as a 
barrier for tumor progression, and that this needs to be overcome in order to allow 
cell cycle reentry and tumorigenesis. However, at this stage low levels of DNA 
damage response are still necessary for the survival of these cells. Based on this 
notion, ATR and Chk1 inhibitors have been developed in order to target cells that 
harbor replication stress. Although they were shown to work for Myc-induced tumors, 
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the inhibitors were found to be totally ineffective in Ras-dependent tumors (Murga et 
al., 2011). The fact that we observe that RasV12 can impair ATR activity could explain 
why ATR inhibitors fail as a treatment to Ras-induced tumors. 
Irrespective of the DDR activation, RasV12 cells still carry large amounts of DNA 
damage that they have to cope with. We have shown that these cells do not depend 
on DNA damage repair pathways for their growth. However, it has been shown that 
extra Chk1 can limit replication stress and promote transformation (López-Contreras, 
et al., 2012). We decided to overexpress Chk1 in RasV12 wing discs and we 
observed increased tissue growth and folding (Fig 3). Although we have not carefully 
analyzed this phenotype, and we do not know whether the cells have less damage 
or are no longer G2 arrested, we believe this is the case. All these results suggest 
that we need to be extremely careful in using DDR inhibitors as therapeutics targets 
in different types of tumors, considering whether the DDR is activated or not and at 
which stage of the tumor progression is the treatment administered.  
 
Figure 3. Grapes overexpression promotes RasV12 tissue growth. Third instar wing 
imaginal discs expressing the indicated transgenes under the control of the hh-Gal4 
driver. Discs were stained for DAPI (Blue), Ci and HA (Green). Quantification of tissue 
growth in terms of posterior / anterior ratio at different induction times.  
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3. Role of ERK in apoptosis inhibition 
3.1. Homeostatic role of ERK in blocking apoptosis. 
Besides its very well-known role in patterning and differentiation, we have shown that 
endogenous levels of ERK protein play a role in protecting cells from apoptosis, both 
in the case of developmental and irradiation induced apoptosis. ERK is commonly 
activated after mitogenic signaling. This will induce proliferation, that will very 
provably generate some replication problems that could elicit a DDR response. We 
believe that ERK plays a role in buffering the apoptotic response induced by this 
damage in order to maintain the integrity of the tissue.  
In the case of an irradiation response, we and others (Mogila, Xia, & Li, 2006) have 
shown that ERK becomes phosphorylated and activated upon irradiation. However, 
the mechanism of ERK activation is not clear yet. We thought that the main suspect 
should be the DNA damage response since it is rapidly activated after damage. 
However, we have shown that ERK phosphorylation in Drosophila is not dependent 
on the activation of neither ATR nor ATM. Different mechanisms for ERK activation 
have been proposed. A possibility is a ROS dependent activation of the EGFR 
receptor (Yan et al., 2015).  Another possible mechanism is that IR can generate 
mitochondrial damage and fission and this in turn, can activate AMPK that 
phosphorylates ERK (J. Wu, Zhang, Wuu, Davidson, & Hei, 2017). We do not have 
any data that points into any of the possibilities, yet it would be interesting and 
relatively manageable to study if any of these proposed mechanisms apply to our 
case. It is also possible that given the relevance of ERK activation in maintaining tissue 
homeostasis, not only one mechanism applies but rather a series of redundant 
signals give rise to the activation of ERK in response to IR.  
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3.2 Pro-tumoral role of ERK in blocking apoptosis.  
In our model, we have shown that RasV12 cells become addicted to ERK oncogenic 
signaling in order to maintain tumor cells alive. Whether these cells have sequestered 
the homeostatic role of ERK to promote their survival or this is a newly acquired 
characteristic of cells with very high levels of ERK we do not know.  
In mammals, there is still some controversy about whether ERK signaling plays a pro-
survival or pro-apoptotic role. Dependent on the cellular context, both effects have 
been observed. However, it is generally accepted that it has a pro-survival function 
in response to irradiation (Dent et al., 2003; Hein, Ouellette, & Yan, 2014; Munshi & 
Ramesh, 2013).  In Drosophila, ERK has been proposed to mediate a pro-survival 
role through the inhibition of the proapoptotic gene hid. And not only this, the 
existence of an ERK-dependent G2 checkpoint in response to DNA damage has 
been proposed (Mogila et al., 2006). This checkpoint is supposed to induce the arrest 
of damaged cells in G2 independently of ATR and Chk1 and might be a relevant 
copying mechanism of RasV12 cells.  
However, to us more important than the mediators of this effect, was how could we 
exploit this ERK dependency as a weakness of tumor cells for cancer treatment.  
 
4. Exploiting oncogene induced replication stress as a 
therapeutic opportunity 
The ability of oncogenes to promote replicative stress and DNA damage has been 
exploited as a way to induce the selective elimination of cancer cells by targeting 
the DDR and different repair mechanisms (Lecona & Fernandez-Capetillo, 2018; 
Puigvert, Sanjiv, & Helleday, 2016). However. some of these approaches have been 
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ineffective in targeting RasV12-tissues (Murga et al., 2011), possibly due to inhibition 
of ATR in these tissues.  
4.1 ERK inhibition to selectively target Ras tissues.  
Given the lack of response of Ras cells to ATR inhibitors, we decided to test an 
alternative approach, where we can exploit the intrinsic characteristics of RasV12 
cells to make them more sensitive to irradiation. We have shown that the combination 
of the endogenous replicative stress and the inhibition of the capacity of ERK to block 
cell death can be exploited to selectively radiosensitize RasV12 cells when compared 
to wild type cells.  
4.1.1 Genetic ERK inhibition. 
We used genetic ERK depletion as a proof of concept. We showed that genetic ERK 
inhibition radiosensitizes RasV12 cells producing cell death of the tissue. We 
measured the amount of apoptosis rather than the growth of the tissue to separate 
the effects of ERK inhibition on tissue growth from its capacity to prevent apoptosis.  
Unfortunately, in most cases ,when tumors are detected in patients they are no longer 
benign. Therefore, we changed our model for a well-established Ras-dependent 
model of transformed neoplastic growth. Unfortunately, in this case genetic ERK 
depletion was not capable of radiosensitizing the cells.  At first, we thought that this 
was due to some emergent feature of this new model, that somehow made the 
neoplastic cells resistant. However, we are inducing tumor formation at the same 
time as depleting ERK which may directly interfere with the tumor formation.  
4.1.2 Chemical ERK inhibition. 
Chemical ERK depletion, by Trametinib, in RasV12, Scribble-i cells could radiosensitize 
the cells. This suggested that the lack of response to genetic ERK inhibition was a 
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problem of induction timing rather than resistance of these cells. Importantly, we 
observed that Trametinib treatment alone was capable of inducing cell death in this 
malignant model. RasV12, Scribble-i discs grow more that RasV12 discs, suggesting 
that they may have overcome the G2 arrest induced by Ras expression. This could 
increase replication stress and DNA damage and lower the time available for DNA 
damage repair, thus making RasV12, Scribble-i cells more sensitive to Trametinib 
treatment. Alternatively, and as mentioned in the results, RasV12, Scribble-i discs 
induce known pro-apoptotic JNK signaling (Igaki et al., 2006). We have also shown 
that they induce high levels of p53 activity. This double pro-apoptotic signaling might 
make them more dependent on ERK signaling for cell survival than RasV12 cells.  
After testing the effects of chemical inhibition in the wing discs, we shifted to a clonal 
model which recapitulates more faithfully the steps of tumor initiation and 
progression. Previous reports had used Trametinib to prevent Ras-dependent tumor 
initiation (Levine & Cagan, 2016). By using this model, we were able to show that 
Trametinib treatment after the tumor has already been established can also prevent 
tumor growth, but more importantly that it promotes apoptosis of the tumor cells. This 
is particularly relevant since ERK inhibition treatments are generally considered to be 
cytostatic rather than cytotoxic. It would be interesting to evaluate whether after 
interruption of Trametinib treatment the remaining tumor cells can reconstitute the 
tumor or not. Latest reports suggest that inhibition of ERK signaling can present a 
complete response even after months of treatment cessation (Brugnara et al., 2018). 
4.1.3 MEK inhibitors in cancer treatment. 
Trametinib has been approved for the treatment of metastatic melanoma mutant for 
BRAF. These tumors are originally treated with BRAF inhibitors, however, they usually 
become resistant to this treatment by activating ERK signaling downstream of RAF 
(Chapman, 2013; Griffin et al., 2017). In order to prevent this effect, the combination 
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of MEK and BRAF inhibitors is used (Flaherty et al., 2012). Currently, Trametinib is 
being clinically tested for the treatment of other types of tumors (Planchard et al., 
2016; Subbiah et al., 2018). However, in these trials, the role of MAPK-ERK signaling 
in preventing irradiation induced cell death is not taken into consideration. Our results 
pave the way for radiotherapy to be considered as a treatment option in order to 
increase the DNA damage induced by the oncogene, in combination with MEK and 
BRAF inhibitors (Fig 4).  
 
Figure 4. Combined MEK inhibitor and IR therapy selectively kills Ras cells. RasV12 
expressing cells reach a balanced state, in which the apoptosis induced by endogenous 
DNA damage is blocked by the high levels of ERK activation. Upon ERK inhibition by 
Trametinib treatment and the induction of DNA damage by irradiation, there is a 
perturbation of the balance towards apoptosis induction which leads to the selective 
killing of RasV12 cells.   
 
 
We have not analyzed the effect of the combination of MEK inhibitors with other DNA 
damaging drugs. However, the fact that ERK has been shown to be upregulated in 
response to not only IR, but also UV light, Hydroxyurea and other damaging agents 
(Razidlo et al., 2009; Tang et al., 2002; Wu et al., 2006; Yan, Black, & Cowan, 2007), 
suggests that MEK inhibition should be effective irrespective of the type of damage 
generated.  
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Ideally, we would like to test our model and the combination of Trametinib and 
irradiation in mouse models or human cell lines in order to further the possible 
applicability of this treatment option.  
 
5. Relevance of non-autonomous autophagy  
The role of autophagy in tumor progression is still under discussion, many reports 
show that autophagy is necessary for tumor growth while others demonstrate that it 
plays the opposite role (Yun & Lee, 2018). This has made people very cautious about 
the use of autophagy as a possible therapeutic target. 
Here we have shown a possible role of autophagy in driving tumor growth. Similarly 
to that observed by (Katheder et al., 2017), autophagy seems to be dependent on 
JAK/STAT signaling. In this pape,r it was shown that the role of JAK/STAT was 
mediated by ROS production. However, in our case, ROS do not seem to play the 
expected role.  
Another paper published in the same year showed a role of autonomous autophagy 
in protecting cells from ROS accumulation thus preventing tumor growth (Manent et 
al., 2017). This led us to think that maybe some of the differences that are observed 
in the role of autophagy could be due to differentiated functions of autonomous and 
non-autonomous autophagy. If this were true it would certainly complicate the use of 
autophagy inhibitors as a treatment option. 
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Conclusions 
Based on the experiments carried out during the past five years and exposed in this 
thesis, we can extract the following conclusions.  
1. RasV12 expression in Drosophila wing imaginal discs induces a benign tissue 
overgrowth.  
2. RasV12 expression promotes G1/S transition and G2 arrest. The later can be 
rescued by String overexpression. 
3. RasV12 cells exhibit characteristics of senescent cells. 
4. RasV12 expression induces replicative stress and DNA damage. 
5. The mechanisms of DNA damage signaling are impaired by RasV12 expression.  
6. RasV12 expressing cells block Dp53-dependent apoptosis in an ERK dependent 
manner.  
7. In wild type tissues, ERK is upregulated, independently of the DDR, upon irradiation.  
8. Homeostatic ERK levels prevent developmental and irradiation-induced apoptosis. 
9. A combination of irradiation and genetic depletion of ERK can be used to 
selectively kill RasV12 cells. 
10. The previous combination is not effective in killing RasV12, scribble malignant 
tissues.  
11. MEK inhibitors can be combined with irradiation to kill RasV12, scribble cells.  
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12. Clonally induced RasV12, scribble mutant tumors can be treated with MEK 
inhibitors to achieve a reduction in tumor burden, a rescue of developmental delay 
and to selectively induce the death of malignant tumor cells. 
13. RasV12 expression causes a non-autonomous induction of DNA damage, 
apoptosis and autophagy.  
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1. Materials 
1.1 Drosophila Strains: 
The following strains were provided by the following sources: (1) Bloomington 
Drosophila Stock Center (BDSC): (2) Vienna Drosophila RNAi Center (VDRC):  
Table 4. List of Drosophila stocks 
ap-GAL4 3041 BDSC 
elav-gal4 8765 BDSC 
en-gal4 30564 BDSC 
hid-EGFP.5'F-WT   50750 BDSC 
hid-EGFP.5'F-WT   50751 BDSC 
Hid-GFP 50750 BDSC 
His2Av-mRFP1 23650 BDSC 
mCherry-atg8 37749 BDSC 
mir277- sponge 61408 BDSC 
PCNA-GFP 25749 BDSC 
Tub-gal80t ts 41598 BDSC 
UAS- His2Av-mKO 53731 BDSC 
UAS- Mlh1 RNAi 32940 BDSC 
UAS-cat A RNAi 24621 BDSC 
UAS-CycE 4781 BDSC 
UAS-dATM RNAi 108074 BDSC 
UAS-dp53-2.1 6584 BDSC 
UAS-ERCC11RNAi 52929 BDSC 
UAS-erkRNAi 34855 BDSC 
UAS-FamcM RNAi 32889 BDSC 
UAS-FancD2 RNAi 56141 BDSC 
UAS-FancI RNAi 32972 BDSC 
UAS-gfpRNAi  35786 BDSC 
UAS-Greatwall RNAiv 34525 BDSC 
UAS-ksr RNAi 41698 BDSC 
UAS-Msh6 RNAi 35737 BDSC 
UAS-mus201 RNAi 35652 BDSC 
UAS-myristoylated-Tomato 32222 BDSC 
UAS-PARP RNAi 57265 BDSC 
UAS-Pms2 RNAi 55614 BDSC 
UAS-pnt RNAi 31936 BDSC 
UAS-PP2A-B RNAi 30512 BDSC 
UAS-PP2AB-29B RNAi 43283 BDSC 
UAS-PP2C1 RNAi 40827 BDSC 
UAS-Rad23 RNAi 51434 BDSC 
UAS-Ras-V12 64196 BDSC 
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UAS-Ras23 RNAi 44031 BDSC 
UAS-sod2 24494 BDSC 
UAS-TFIIH RNAi 53345 BDSC 
UAS-tos RNAi 33934 BDSC 
UAS-XPA RNAi 51806 BDSC 
UAS-XPF RNAi 55313 BDSC 
UAS-XRCC1 RNAi 61359 BDSC 
ub-EGFP-E2F11-230, ub-RFP-CycB1-266 55123 BDSC 
ub-EGFP-E2F11-230, ub-RFP-CycB1-266 55124 BDSC 
UAS-Rad54 RNAi 104323 VDRC 
UAS-scribRNAi  105412 VDRC 
UAS-scrib RNAi 105412 VDRC 
UAS-lig4 RNAi 107044 VDRC 
UAS-mei-41RNAi (UAS-dATRRNAi) 11251 VDRC 
UAS-grpRNAi (UAS-dChk1RNAi) 12680 VDRC 
UAS-rad51 RNAi 13362 VDRC 
UAS-mus210 RNAi 15696 VDRC 
UAS-mus81 RNAi 33688 VDRC 
UAS–dp53RNAi  38235 VDRC 
UAS-EME1 RNAi 38750 VDRC 
UAS-erkRNAi  43123 VDRC 
UAS-ent2 RNAi 47536 VDRC 
UAS-ent3 RNAi 47536 VDRC 
UAS-ent1 RNAi 51055 VDRC 
UAS-cnt RNAi 7374 VDRC 
DomeDN  (Brown et al., 2001) 
Mini-cic  (Moreno et al., 2019) 
Upd-lacZ  (Jiang et al., 2011) 
Stat92E-GFP  (Bach et al., 2007) 
UAS-dE2F1 UAS-DP  (Neufeld et al., 1998) 
gstD-GFP  (Sykiotis & Bohmann, 2008) 
UAS-RasV12;FTR82B scrib-1  (Cordero et al., 2010) 
UAS-Pi3K DN  (Leevers et al.,1996)  
ey flp; Act>y+>Gal4, UAS-GFP; 
FRT82B TubGal80 
 (Pagliarini & Xu, 2003) 
UAS-miRHG  (Siegrist et al., 2010) 
UAS-upd RNAi  (Ayala-Camargo et al., 
2013) 
Tub-RPA-GFP  (Murcia et al., 2019) 
Tub-Mre11-GFP  (Murcia et al., 2019) 
Tub-Rad50- RFP  (Murcia et al., 2019) 
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1.2 Antibodies  
Table 5. List of primary and secondary antibodies 
Mouse anti-dMMP1  14A3D2 DSHB 
Rat anti-E-cadherin  DCAD2 DSHB 
Mouse anti-P-H2Av  UNC93-5.2.1 DSHB 
Rabbit anti-P-H2Av  S137 Rockland Immunochemicals 
Rat anti-Ci  2A1 DSHB 
Rabbit anti-CycE  Sc-481 Santa Cruz Biotechnology 
Rabbit anti-Gal4 Sc-577 Santa Cruz Biotechnology 
Rabbit polyclonal anti-p-ERK  4370 Cell Signaling Technology 
Rabbit anti-cleaved Dcp1  9578-s Cell Signaling Technology 
Rabbit anti-pAkt Ser 505 Cell Signaling Technology 
Rabbit anti-PH3 Ser 10 Merck  
Rabbit anti-Capicua  (Fores et al., 2017) 
Mouse anti-CycB  F2F4 DSHB 
Mouse anti- Cyc A A12 DSHB 
Mouse anti-ß-gal 40.1A DSHB 
Rabbit anti-dsRed 632496 Clonetech 
Alexa fluor 488-conjugated AffiniPure 
Donkey Anti-Mouse IgG (H+L) 
 Jackson ImmunoResearch 
Cy2 AffiniPure Donkey Anti-Rabbit IgG 
(H+L) 
 Jackson ImmunoResearch 
Cy3 AffiniPure Donkey Anti-Mouse IgG 
(H+L) 
 Jackson ImmunoResearch 
Cy3 AffiniPure Donkey Anti-Rabbit IgG 
(H+L) 
 Jackson ImmunoResearch 
Cy5 AffiniPure Donkey Anti-Rat IgG (H+L)  Jackson ImmunoResearch 
Developmental Studies Hybridoma bank (DSBH) 
1.3 Other reagents  
Table 6. List of reagents 
In Situ Cell Death Detection Kit, 
Fluorescein (TUNEL) 
11684 795910 Roche  
Click-iT™ Plus EdU Alexa Fluor™ 647 
Imaging Kit 
C10640 Invitrogen 
Click-iT™ Plus EdU Alexa Fluor™ 488 
Flow Cytometry Assay Kit 
C10632 Invitrogen 
Comet Assay Kit 4250-050K Trevigen 
DAPI 28718-90-3 Sigma Aldrich 
Trametinib HY-10999A MedChem Express 
CellEventTM Senescence Green detection 
kit 
C10850 Invitrogen 
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2. Methods 
2.1 Fly husbandry. 
Generally, flies were allowed to lay eggs on standard fly food for 24 hours at 18°C, 
larvae were maintained at 18°C for 6 days and switched to 29ºC 3 days before 
dissection (Fig 1). For 15h inductions flies were kept at 18ºC for 9 days and switched 
at 29ºC 15h prior to dissection. If necessary Trametinib as administered 1 day after 
transgene expression and 2 days prior to dissection. Irradiation treatment was 
implemented between 2 and 5 hours prior to dissection (Fig 1).  
 
Figure 1. Transgene expression protocol 
 
To generate RasV12, scrib-/- clones, flies carrying the MARCM 82B green tester 
(eyFLP1; act>y+>Gal4, UAS-GFP; FRT82B tub-Gal80 (Pagliarini & Xu, 2003) were 
crossed with flies of the following genotype UAS-RasV12; FRT82B scrib1 flies as 
described in (Mundorf & Uhlirova, 2016). Flies were allowed to lay eggs during 24 h 
at 25ºC and to develop at this same temperature. As in (Willoughby et al., 2013), 
Trametinib was added 4 days after egg laying to the food at a 2µM final 
concentration. Larvae were analyzed 6, 8, 10 and 12 days after egg laying (Fig 2). 
For pupariation measurements, the same induction protocol was used but flies were 
allowed to lay eggs for 4 hours. Trametinib treatment was administered ad least one 
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day after clone induction and flies were evaluated2, 4, 6 or 8 days after treatment 
(Fig 2).  
 
Figure 2. Clone induction protocol 
 
2.2 Treatments  
2.2.1 Ionizing Radiation (IR) treatments and quantifications.  
Irradiations were carried out in an YXLON MaxiShot X-ray system at the standard 
dose of 40Gy and at lower doses of 8, 12, 16 and 24 Gy. Number of pH2Av foci, 
mitotic (pH3-positive) cells and apoptotic (Dcp1-positive) cells were analysed 5 hours 
after the IR treatment and these numbers were normalized to the area. 
Measurements in control untreated wing discs grown in parallel were carried out in 
every experiment. . 
2.2.2 Trametinib treatment 
Flies were allowed to lay eggs on fly food for 24h and resulting larvae were 
maintained at 18°C for 6 days. Trametinib (1µM final concentration) was added to 
vials 1 day after transgene induction. 1,5µl of Trametinib (MedchemExpress) 10 mM 
(or 1.5 µl DMSO as a control) was diluted in 200 µl of H2O and added to vials. 
Trametinib was diluted in DMSO and used at concentrations that ensured that the 
final DMSO concentration was lower than 0.05%. The final concentration of DMSO 
was 0.01%. 
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2.3 Immunostaining and labeling 
2.3.1 Immunostaining  
Wing imaginal discs of third instar larvae were dissected in cold PBS, fixed with 
formaldehyde 4% for 20 minutes, rinsed three times in PBT (PBS + 0.1% Triton) and 
blocked for 1 hour in BBT (PBS + 0.1% Triton+ 0,3% BSA + 250mM NaCl). Then discs 
were incubated with primary antibodies overnight, rinsed with BBT and incubated 
with secondary antibodies for 2 hours. After 3 PBT washes, discs were kept on 
mounting media (80ml glycerol + 10ml PBS 10x + 0,8 ml N-propyl-gallate 50%).  
Zeiss LSM780 and Zeiss LSM 880 with airyscan confocal microscopes were used to 
take high resolution images.  
2.3.2 TUNEL assay 
TUNEL analysis was performed as described in (Milan et al., 1997) used to label the 
DNA breaks produced in apoptotic cells (Cat. No. 11 684 795 910, Roche). 
2.3.3 EdU labelling 
Click-iT™ Plus EdU Alexa Fluor™ 647 Imaging Kit from Invitrogen (C10640) was 
performed, following the manufacturer’s indications, to measure DNA synthesis (S 
phase) in proliferating cells. EdU (5-ethynyl-2 -´deoxyuridine) provided in the kit is a 
nucleoside analog of thymidine and is incorporated into DNA during active DNA 
synthesis. Detection is based on a click reaction. 
2.3.4 Senescence labelling 
CellEvent™ senescence green detection kit from Invitrogen (C10850) was used to 
detect senescence-associated b-galactosidase (SA-b-gal) activity following the 
manufacturer’s instructions. Wing discs were fixed with 4% PFA, washed (1% BSA in 
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PBS) and then incubated in working solution for 2h at 37ºC. Discs were then washed 
in PBS and mounted for confocal imaging. 
2.4 Image processing and analysis 
Fiji [National Institute of Health (NIH) Bethesda, MD] was used to measure the size 
of the Anterior (A), Dorsal (D) compartments (based on Ci and MyrT expression 
respectively), or the whole wing discs (based on DAPI staining), and to manually 
count mitotic cells (PH3 positive cells) or DDR active cells (pH2Av positive cells). Image 
stacks were obtained using a Zeiss LSM780 confocal microscope, 25X glycerol 
immersion objective with 4 µm per optical section to cover the entire thickness of 
each disc, maximum intensity Z-projection was performed on the stacks prior to 
quantification. Control wing discs grown in parallel and subjected to the same 
experimental conditions (temperature and time of transgene induction) were always 
quantified in parallel. At least 10 wing discs per genotype were scored. 
2.4.1 Fly-FUCCI quantification:  
Images were taken using a Zeiss LSM780 confocal microscope with a 25X glycerol 
immersion objective. Apical sections of the wing discs where imaged under identical 
confocal settings. A region of interest was delimited within the asynchronously 
dividing cells of the wing pouch area, carefully avoiding the zone of non-proliferating 
cells (ZNC) both in wild type and RasV12-expressing discs. Red, green or red and 
green cells were manually quantified. RasV12 and control wing discs were grown in 
parallel and subjected to the same experimental conditions. At least 10 wing discs 
per genotype were scored. 
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2.4.2 Measurement of pERK and Cic levels 
All samples to be compared were processed in parallel. Apical images were 
obtained using identical settings in a ZEISS LSM780 confocal microscope. Mean 
pERK or Capicua intensity was analyzed by FIJI software (NIH, USA). Confocal settings 
were adjusted to avoid any saturated pixels with maximal intensity. 
2.4.3 Comet assay  
The Comet Assay Kit (Trevigen, Catalog #4250-050K) was performed as described 
in (Rimkus & Wassarman, 2018) to detect Double Strand Breaks (DSBs) in the 
molecule of DNA at a single cell level. Comets were imaged using an ECLIPSE E800 
+ OLYMPUS DP72 upright microscope with a 10X objective. For each sample, >200 
comets were imaged and analyzed using CaspLab Software. Damage was 
quantified as the comet tail moment, which is defined as the product of the tail length 
and the fraction of total DNA in the tail (Tail moment=tail length x % of DNA in the 
tail). Unpaired equal-variance two-tail t-test was performed using GraphPad Prism 7 
Project to compare comet tail moment between pairs of samples. The experiment 
was conducted 3 times with similar results. 
2.5 Flow Cytometry analysis 
Third instar larvae of each genotype were dissected in cold PBS. To label S-phase 
cells we used Click-iT™ Plus EdU Alexa Fluor™ 488 Flow Cytometry Assay Kit 
(C10632), following the manufacturer´ s indications with some modifications. After 
incubating larvae with 10µM EdU in PBS for 5 min, tissues were trypsinized in the 
presence of EDTA at 32ºC for 45 min as described in (Neufeld et al., 1998). Once 
Click-iT™ reaction was performed, permeabilized cells were stained with DAPI 
1mg/ml and RNase 100 mg/ml and incubated for 1h at RT. Fluorescence was 
determined by flow cytometry using a FacsAria I SORP sorter (Beckton Dickinson, San 
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Jose, California). Excitation with the blue line of the laser (488 nm) permits the 
acquisition of scatter parameters, green (530 nm) fluorescence from GFP and red 
(635 nm) fluorescence from Tomato. A UV laser (350nm) was used for DAPI excitation. 
Doublets were discriminated using an integral/peak dotplot of DAPI fluorescence. 
Optical alignment was on optimized signal from 10 µm fluorescent beads 
(Flowcheck,Coulter Corporation, Miami, FL). DNA analysis (cell cycle) on single 
fluorescence histograms was done using FlowJo, LLC Software.  
2.6 QuantSeq 
Wing imaginal discs expressing MyrT and RasV12 or MyrT and GFP-i under the 
control of the ap-Gal4 driver were dissected and FACS sorted to isolate the transgene 
expressing cells. 150.000 cells per replicate were collected in in Lysis Buffer (20 mM 
DTT, 10 mM Tris.HCl ph 7.4, 0.5% SDS, 1μg/μl proteinase K), incubated 15 min at 65ºC 
and stored at -80ºC. RNA extraction and library preparation was performed by the 
Functional Genomic Core Facility at IRB Barcelona. RNA was extracted using RNA 
Clean XP bead suspension (Agencourt Bioscience), digested with DNAse-I, cleaned-
up by a 2nd pull-down and eluted in water. Library preparation was performed from 
a 150 ng total RNA using the kit Quant Seq 3' mRNA-Seq Library Prep for Illumina 
(Lexogen) following the manufacturer’s instructions. 100 bp SE sequencing was 
performed in an Illumina HiSeq 2500 by the VBCF NGS Unit. Data was analyzed at 
IRB Barcelona's Biostatistics and Bioinformatics Unit. Unaligned bam files were 
converted to FastQ files using Bedtools 2.17. Original 100bp reads were trimmed 
down to 50bp with trimmomatic 0.33 to reduce trailing PolyA contamination. FastQ 
files were aligned against the dm6 genome using STAR 2.3.0e, using default options. 
Aligned reads were imported in R using RSamtools to perform further quality control 
steps. Only reads with MapQ>0 (aligning to 10 sites or less) were kept for 
downstream procedures. To obtain per-sample expression estimates we used the 
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summarize Overlaps function from the Genomic Alignments package, using the 
Intersection Not Empty mode and single end strand specific options. Counts were 
used to perform a differential expression analysis using the DESeq2 package, 
previously removing genes without reads in any of the analyzed samples, and using 
the default options. Output results were filtered to consider differentially expressed 
genes with |FC|>2 and Benjamini-Hochberg adjusted pvalue < 0.05. FastQC v011 
was used to perform a quality control overview of FastQ files and aligned BAM files. 
Binary tracks in BigWig format were generated with the tracklayer package, both for 
individual and pooled samples by group. The log2FC information was used to rank 
all genes in the genome with n reads>0 and a Gene Set Enrichment Analysis 
(Subramanian et al., 2005)was performed with Gene Ontology Biological Processes 
(Gene Ontology Consortium, 2015), GOSLIM and KEGG collections. 
2.7 Statistical Analysis 
Statistical analysis was generally performed by Students t-test. Differences were 
considered significant when p values were less than 0.001 (***), 0.01 (**), or 0.05 (*). 
All genotypes included in each histogram were analyzed in parallel. For comparisons 
of differences, Wald test derived from the linear model after quadratic root 
transformation was used to perform pairwise comparisons and to assess the 
significance of the interaction. Results for pairwise comparisons were adjusted by 
multiple comparisons using Shaffer’s method. A 5% level was chosen as significance 
threshold. All data points were graphed in Prism 7.0 (Graphpad) statistical software. 
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Supporting tables 
Table 1. GSEA positively regulated gene sets 
 
POSITIVELY REGULATED GENE SETS SIZE NES FDR  q-val 
    
Epithelial structure maintenance 17 1,958 0,133 
ErbB signaling pathways 58 1,906 0,158 
Epidermal growth factor receptor signaling pathways  58 1,868 0,189 
Trachea development  21 1,674 0,212 
Transmembrane receptor protein tyrosine kinase  
signaling pathway  137 1,628 0,212 
Regulation of neurogenesis 113 1,642 0,214 
Multicellular organismal homeostasis  40 1,629 0,215 
Regulation of epidermal growth factor receptor signaling  
pathway  33 1,675 0,216 
Establishment of ommatidial planar polarity 59 1,682 0,216 
Torso signaling pathway  33 1,643 0,217 
R3/R4 cell fate commitment 16 1,617 0,217 
Photoreceptor cell development  92 1,624 0,218 
Sensory organ development  419 1,619 0,218 
Gastrulation with mouth forming first  35 1,621 0,218 
Peripheral nervous system development  87 1,688 0,219 
Actin polymerization or depolymerization  38 1,630 0,219 
Response to wounding  80 1,683 0,220 
Gastrulation involving germ band extension  35 1,643 0,221 
Compound eye photoreceptor fate commitment  55 1,663 0,222 
R7 cell differentiation  48 1,633 0,222 
Neuroblast division  34 1,631 0,222 
Ommatidial rotation  26 1,648 0,222 
Regulation of stress-activated  38 1,603 0,223 
Biological adhesion  201 1,676 0,223 
Regulation of ErbB signaling pathway 33 1,645 0,224 
Asymmetric neuroblast division 33 1,665 0,224 
Defense response 246 1,604 0,224 
Negative regulation of epidermal growth factor receptor  
signaling  21 1,689 0,224 
Death  254 1,606 0,225 
Neural precursor cell proliferation  59 1,633 0,226 
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Regulation of response to stress 114 1,609 0,226 
Regulation of JNK cascade  37 1,607 0,227 
Adherens junction organization 27 1,611 0,227 
Neuroblast proliferation  58 1,648 0,228 
Epithelial tube morphogenesis 90 1,598 0,229 
Cell adhesion  193 1,691 0,230 
Notch signaling pathway 101 1,649 0,233 
Toll signaling pathway  42 1,593 0,234 
Photoreceptor differentiation  165 1,589 0,235 
Apoptotic process  153 1,585 0,235 
Eye photoreceptor cell fate commitment  56 1,650 0,236 
Response to pheromone  20 1,696 0,237 
Chaeta morphogenesis  46 1,692 0,238 
Cell death  251 1,590 0,238 
Transition metal ion homeostasis  19 1,586 0,238 
Regulation of stress-activated protein kinase signaling  
cascade  38 1,652 0,239 
R3/R4 cell differentiation  17 1,702 0,246 
Negative regulation of cell fate specification  18 1,576 0,247 
Negative regulation of ErbB signaling pathway 21 1,696 0,248 
Response to starvation  48 1,573 0,249 
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Table 2. GSEA negatively regulated gene sets 
 
NEGATIVELY REGULATED GENE SETS SIZE NES FDR q-val 
DNA replication 80 -2,132 0,009 
Posterior head segmentation 15 -1,970 0,028 
Protein-DNA complex subunit organization 48 -1,959 0,029 
Nucleosome organization 27 -1,933 0,032 
DNA-dependent DNA replication 53 -1,971 0,032 
Nucleosome assembly 17 -1,918 0,035 
Eggshell chorion gene amplification 16 -1,935 0,035 
Potassium ion transport 32 -1,974 0,039 
Cell cycle DNA replication 25 -1,979 0,047 
DNA integrity checkpoint 74 -1,862 0,054 
Chromatin assembly or disassembly 32 -1,866 0,056 
Anterior/posterior pattern specification, imaginal disc 19 -1,871 0,057 
Protein-DNA complex assembly 34 -1,990 0,061 
DNA amplification 18 -1,844 0,063 
Mitotic G2 DNA damage checkpoint 60 -1,821 0,075 
Chromatin assembly 26 -1,794 0,081 
Regulation of DNA metabolic process 31 -1,797 0,083 
Positive regulation of intracellular protein transport 22 -1,798 0,087 
DNA damage checkpoint 71 -1,768 0,087 
mRNA export from nucleus 21 -1,777 0,087 
Regulation of transcription factor import into nucleus 22 -1,684 0,088 
Canonical wnt receptor signaling pathway 29 -1,678 0,088 
Neuropeptide signaling pathway 26 -1,686 0,088 
Regulation of transcription elongation from RNA polymerase  
II promoter 15 -1,781 0,089 
Regulation of DNA-dependent transcription, elongation 19 -1,679 0,089 
RNA export from nucleus 26 -1,686 0,090 
DNA conformation change 77 -1,680 0,090 
Protein localization to nucleus 64 -1,761 0,090 
Head segmentation 26 -1,768 0,091 
Mitotic DNA integrity checkpoint 64 -1,799 0,091 
DNA endoreduplication 19 -1,687 0,091 
RNA splicing, via transesterification reactions with bulged  
adenosine as nucleophile 212 -1,689 0,091 
NFAT protein import into nucleus 15 -1,671 0,093 
Somatic muscle development 47 -1,751 0,093 
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Positive regulation of NFAT protein import into nucleus 15 -1,689 0,093 
Protein targeting to nucleus 60 -1,744 0,094 
Serine family amino acid metabolic process 16 -1,691 0,094 
Protein import into nucleus 60 -1,695 0,094 
Transcription factor import into nucleus 22 -1,698 0,094 
DNA packaging 68 -1,693 0,095 
Mitotic DNA damage checkpoint 63 -1,745 0,095 
Regulation of chromatin silencing 24 -1,738 0,095 
mRNA transport 29 -1,752 0,096 
Cell cycle checkpoint 89 -1,699 0,096 
Regulation of mRNA splicing, via spliceosome 57 -1,701 0,097 
Nuclear import 61 -1,722 0,097 
Positive regulation of protein import into nucleus 18 -1,733 0,097 
RNA splicing, via transesterification reactions 213 -1,712 0,097 
G2 DNA damage checkpoint 61 -1,724 0,098 
Lymph gland development 29 -1,702 0,099 
Regulation of mRNA processing 62 -1,704 0,100 
mRNA splicing, via spliceosome 212 -1,712 0,100 
Positive regulation of nucleocytoplasmic transport 18 -1,716 0,100 
Head development 28 -1,706 0,100 
Regulation of NFAT protein import into nucleus 15 -1,726 0,100 
Transcription elongation from RNA polymerase 
 II promoter 19 -1,654 0,106 
Larval lymph gland hemocyte differentiation 15 -1,647 0,109 
Regulation of cell cycle process 173 -1,649 0,109 
RNA splicing 220 -1,642 0,110 
Positive regulation of transcription factor import into  
nucleus 18 -1,644 0,111 
mRNA processing 263 -1,637 0,113 
Regulation of RNA splicing 61 -1,619 0,129 
DNA biosynthetic process 26 -1,615 0,131 
Cardiocyte differentiation 29 -1,608 0,134 
Larval locomotory behavior 19 -1,610 0,134 
Mitotic cell cycle checkpoint 77 -1,603 0,137 
Regulation of alternative mRNA splicing, via  
spliceosome 50 -1,595 0,142 
Regulation of gene silencing 44 -1,596 0,143 
Trunk segmentation 18 -1,586 0,150 
G-protein coupled receptor signaling pathway 145 -1,573 0,163 
Alternative mRNA splicing, via spliceosome 51 -1,571 0,163 
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Nucleocytoplasmic transport 96 -1,563 0,171 
Nuclear transport 96 -1,559 0,174 
Regulation of intracellular protein transport 36 -1,550 0,183 
Mesoderm morphogenesis 29 -1,547 0,184 
mRNA metabolic process 281 -1,537 0,190 
DNA metabolic process 265 -1,540 0,191 
Cuticle development involved in chitin-based cuticle  
molting cycle 16 -1,538 0,193 
Negative regulation of cell cycle phase transition 102 -1,533 0,194 
Chromosome condensation 41 -1,524 0,202 
Positive regulation of intracellular transport 28 -1,525 0,203 
Post-embryonic hemopoiesis 18 -1,516 0,211 
Larval chitin-based cuticle development 15 -1,494 0,228 
Gonad development 57 -1,495 0,229 
Larval lymph gland hemopoiesis 18 -1,497 0,229 
Ribonucleoside monophosphate biosynthetic process 37 -1,498 0,230 
RNA processing 357 -1,499 0,230 
Nucleoside monophosphate biosynthetic process 38 -1,500 0,232 
Negative regulation of cell cycle process 106 -1,486 0,236 
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Table 3. Transmembrane receptor tyrosin kinase signalling pathway 
 
Symbol Gene Name Fold change 
(Log 2) 
pnt pointed   4,187 
sty sprouty 3,866 
aos argos 2,698 
edl ETS-domain lacking 2,618 
kek1 Kekkon 1 2,081 
E(spl)m8-HLH Enhancer of split m8, helix-loop-helix 1,792 
ImpL2 Ecdysone-inducible gene L2 1,704 
fog folded gastrulation 1,642 
brn brainiac 1,612 
peb pebbled 1,629 
Pvf3 PDGF- and VEGF-related factor 3 1,480 
Mmp2 Matrix metalloproteinase 2 1,437 
Alk Anaplastic lymphoma kinase 1,195 
btl breathless 1,082 
rho rhomboid 1,080 
Pvf2 PDGF- and VEGF-related factor 2 0,994 
ato atonal 0,961 
Fas2 Fasciclin 2 0,960 
ru roughoid 0,925 
Rho1 Rho1 0,804 
cv-c crossveinless c 0,718 
melt melted 0,694 
Sulf1 Sulfated 0,627 
Ras85D Ras oncogene at 85D 0,605 
Dab Disabled 0,585 
boss bride of sevenless 0,549 
Socs36E Suppressor of cytokine signaling at 36E 0,530 
Hrs Hepatocyte growth factor regulated tyrosine kinase substrate 0,498 
Pvr PDGF- and VEGF-receptor related 0,488 
sNPF short neuropeptide F precursor 0,465 
Egfr Epidermal growth factor receptor 0,453 
spi spitz 0,451 
pum pumilio 0,418 
Nrk Neurospecific receptor kinase 0,415 
hkb huckebein 0,411 
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Table 4. DNA replication class 
 
Symbol Gene Name Fold change 
(Log 2) 
dup double parked -1,142 
RnrS Ribonucleoside diphosphate reductase small subunit -1,140 
dpa disc proliferation abnormal -0,970 
Caf1-180 Chromatin assembly factor 1, p180 subunit -0,919 
Mcm3 Minichromosome maintenance 3 -0,890 
Mcm2 Minichromosome maintenance 2 -0,836 
Mcm5 Minichromosome maintenance 5 -0,800 
Orc2 Origin recognition complex subunit 2 -0,696 
Mcm7 Minichromosome maintenance 7 -0,652 
Mcm10 Minichromosome maintenance 10 -0,646 
RnrL Ribonucleoside diphosphate reductase large subunit -0,642 
Pdp1 PAR-domain protein 1 -0,575 
hd humpty dumpty -0,556 
Rbf Retinoblastoma-family protein -0,546 
geminin geminin -0,535 
RecQ4 RecQ4 helicase -0,532 
fs(1)Ya female sterile (1) Young arrest -0,521 
cutlet cutlet -0,520 
Mcm6 Minichromosome maintenance 6 -0,514 
Gnf1 Germ line transcription factor 1 -0,512 
DNA-ligI DNA ligase 1 -0,503 
DNApol-α60 DNA polymerase alfa 60 -0,484 
rec recombination-defective -0,434 
DNApol-α180 DNA polymerase alfa 180 -0,430 
Cdc6 Cdc6 -0,422 
RpA-70 Replication Protein A 70 -0,414 
dre4 dre4 -0,406 
Dref DNA replication-related element factor -0,400 
plu plutonium -0,382 
Mes4 Mesoderm-expressed 4 -0,359 
Orc4 Origin recognition complex subunit 4 -0,343 
RfC38 dILP-inhibitor -0,339 
RPA2 Replication protein A2 -0,320 
CycE Cyclin E -0,319 
DNApol-α73 DNA polymerase alfa 73 -0,297 
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NfI Nuclear factor I -0,291 
pita pita -0,276 
DNApol-δ DNA polymerase delta -0,276 
Orc1 Origin recognition complex subunit 1 -0,273 
DNApol-ε DNA polymerase epsilon -0,272 
Top2 Topoisomerase 2 -0,260 
CDC45L CDC45L -0,247 
Btk29A Btk family kinase at 29A -0,246 
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Resumen en Castellano 
La mayoría de tumores sólidos presentan signos de inestabilidad genómica. Se ha 
propuesto que la activación de oncogenes puede generar inestabilidad genómica 
mediante la inducción de estrés replicativo. En esta tesis hemos demostrado que la 
expresión de una forma constitutivamente activa del oncogén RAS en células 
epiteliales de Drosophila promueve una aceleración de la transición entre las fases 
G1 y S del ciclo celular. Esto lleva a una inducción de estrés replicativo y deriva en 
inestabilidad genómica. El daño en el ADN resultante de este proceso debería de 
activar la respuesta al daño en el ADN, sin embargo, esta se encuentra bloqueada. 
Además, la expresión de RasV12 inhibe la muerte celular gracias a los altos niveles 
de activación de ERK.  
Ras es uno de los oncogenes mas comúnmente mutados, sin embargo seguimos 
sin terapias para tratar tumores dependientes de Ras que sean seguras y efectivas. 
Con esto en mente, y basándonos en nuestros resultados anteriores, decidimos 
tratar de explotar en daño en el ADN presente en estas células para destruirlas de 
forma selectiva. A estos efectos, indujimos más daño mediante irradiación e 
inhibimos la expresión ERK para promover la muerte de estas células. Usamos esta 
estrategia tanto en tumores benignos como malignos y en ambos casos logramos 
destruir de forma selectiva las células tumorales. Proponemos que los inhibidores 
de MEK, que se usan para el tratamiento de melanomas metastáticos, podrían 
combinarse con radiación para mejorar los efectos terapéuticos.  
A parte de los efectos autónomos descritos con anterioridad, también hemos 
observado que la expresión de RasV12 induce un fenotipo no autónomo. Las células 
normales adyacentes a las células Ras presentan signos de daño en el ADN, 
apoptosis y autofagia. El papel de estos efectos no autónomos no está claro, 
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hipotetizamos que podrían jugar un papel en sustentar metabólicamente el 
crecimiento del tumor. 
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